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4-1BB Tumor necrosis factor receptor superfamily member 9  
Ab Antibody 
ADCC Antibody-dependent cellular cytotoxicity 
APC Antigen presenting cell 
ATPP Antibody-targeted pathogen-derived peptide 
B-ALL B cell acute lymphoblastic leukemia 
Bcl-2 B cell lymphoma-2 protein 
Bcl-XL B cell lymphoma-extra large protein 
BiTE Bispecific T cell engager 
BMLF1 BamHI-M leftward reading frame 1  
CAR-T Chimeric antigen receptor T cell 
CCR Chemokine receptor 
CD Cluster of differentiation 
CD40L CD40 ligand 
CD95L CD95 ligand 
CDC Complement-dependent cellular cytotoxicity 
CDCP1 CUB domain-containing protein 1 
CDR Complementarity determining region 
CEA Carcinoembryonic antigen 
cFLIP Cellular FLICE-inhibitory protein 
CH Constant domain of the antibody heavy chain 
CL Constant domain of the antibody light chain 
CMV Cytomegalovirus 
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T lymphocyte-associated protein 4 
DAMPs Danger-associated molecular patterns 
DC Dendritic cell 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
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DNA Deoxyribonucleic acid 
EBV Epstein-Barr virus 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor  
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
ELISPOT Enzyme-Linked ImmunoSpot 
EMT Epithelial-mesenchymal transition 
EpCAM Epithelial cell adhesion molecule 
ER Endoplasmic reticulum 
ERAP1/2 (ER)-associated aminopeptidases 1 or 2 
ET-ratio Effector-to-target ratio 
Fab’ Fragment antigen binding 
FACS Fluorescence-activated cell screening/sorting 
FBS Fetal bovine serum 
Fc Fragment crystallizable 
FcRn Neonatal Fc-receptor 
FcγR Fc-gamma receptor 
FDA Food and Drug Administration 
FELASA Federation of Laboratory Animal Science Associations 
FGF Fibroblast growth factor 
FRET Fluorescence resonance energy transfer 
GITR Glucocorticoid-induced TNFR-related protein 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GvHD Graft-versus-host disease 
HER2 Human epidermal growth factor receptor 2 
HLA Human leukocyte antigen 
HMGB1 High mobility group box 1  
HPV Human papillomavirus 
i.p.  Intraperitoneal 
i.v.  Intravenous 






IgG Immunoglobulin G 
IL Interleukin 
INF Influenza A 
iNOS Inducible nitric oxide synthetase 
LAG3 Lymphocyte-activation gene 3 
LCL Lymphoblastoid cell line 
LCMV Lymphochoriomeningitis Virus 
LDH Lactate dehydrogenase 
LMP2 Latent membrane protein 2 
mAb Monoclonal antibody 
MAGE Melanoma-associated antigen 
MCSP Melanoma-associated chondroitin sulfate proteoglycan 
MDSC Myeloid-derived suppressor cell 
MED Minimum effective dose 
MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
mRNA Messenger ribonucleic acid 
NK Natural killer 
NO Nitric oxide 
NP Nucleoprotein 
NSCLC Non-small cell lung cancer 
OVA Ovalbumin 
OX40 Tumor necrosis factor receptor superfamily, member 4 
PAMPs Pathogen-associated molecular patterns 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PD1 Programmed cell death protein 1 
PD-L1 Programmed cell death ligand 1 
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PDGF Platelet-derived growth factor 
PGE2 Prostaglandin E2 
PI3K Phosphatidylinositol-3-kinase 
pRB Retinoblastoma protein 
PRR Pattern recognition receptor 
RAG-1/2 Recombinase activating gene 1 or 2 
RAS Rat sarcoma viral oncogene homolog 
ROS Reactive oxygen species 
s.c. Subcutaneous 
scFv Single-chain variable fragment 
SPDP N-Succinimidyl 3-(2-pyridyldithio)-propionate 
TAM Tumor-associated macrophage 
TAP Transporter associated with antigen processing 
TCR T cell receptor 
TGFβ Tumor growth factor-β 
Th1 Type 1 T helper cell 
Th17 Type 17 T helper cell 
Th2 Type 2 T helper cell 
TIL Tumor infiltrating lymphocyte 
TIM3 T-cell immunoglobulin and mucin-domain containing-3 
TNFα Tumor necrosis factor-α 
TRAIL TNF-related apoptosis-inducing ligand 
Treg Regulatory T cell 
TRP-2 Tyrosinase-related protein 2 
VEGF Vascular endothelial growth factor 
VH Variable domain of the antibody heavy chain 
VL Variable domain of the antibody light chain 
wt Wild type 
XIAP X-linked inhibitor of apoptosis protein 
Zap70 Zeta-chain-associated protein kinase 70 





The work presented in this thesis aimed at the development of antibody 
immunoconjugates for the delivery in tumor cells of highly immunogenic T cell 
epitopes that mediate the antigen-specific recognition by tumoricidal T cells. For this 
purpose, antibody-targeted pathogen-derived peptides (ATPPs) were generated by 
conjugating immunodominant, cysteine-containing MHC class I peptides from 
Epstein-Barr or Influenza A virus to tumor antigen-specific antibodies via a disulfide 
bond. The integral membrane protein CUB domain-containing protein 1 (CDCP1) 
was chosen as proof of concept target, as it is upregulated on various cancer types 
and known to efficiently internalize after antibody binding.  
After binding to the target and subsequent internalization of ATPPs, fluorescence 
resonance energy transfer (FRET) imaging revealed that delivered peptides are 
released upon disulfide reduction in an early endosomal compartment, where they 
can be loaded into recycling MHC class I complexes. Transport of these MHC-
peptide complexes to the cell surface triggers activation of human peptide-specific 
cytotoxic CD8+ T cells as revealed by interferon-γ ELISA and ELISPOT. Moreover, 
peptide-specific CD8+ T cells from human donors efficiently lysed ATPP-treated 
tumor cell lines of various cancer types in a target-dependent manner in vitro. 
Importantly, targeting of different tumor antigens (e.g. CD138) was equally efficient. 
The possibility to utilize various peptides with differing HLA-restrictions further 
highlights the broad applicability of the ATPP approach for T cell mediated targeting 
of cancer. The usage of a non-cleavable construct or an extended peptide that can 
not bind to MHC class I molecules additionally revealed the importance of disulfide-
dependent peptide release and epitope delivery independent of the classical MHC 
class I antigen processing pathway.  
In vivo, ATPPs mediated approximately 60% tumor growth inhibition of established, 
PD-L1 expressing MDA-MB231 xenografts after 3 weeks of treatment in combination 
with αPD1-mAb therapy and adoptive transfer of human, peptide-specific CD8+ T 
cells in NOG mice. These data indicate the potential of ATPPs as novel 
immunotherapeutic agents, which can be employed to redirect pre-existing virus-
specific memory T cells against cancer. Since the immune response will be directed 
against an exogenous, viral antigen, ATPP therapy reduces the risk for autoimmune 
side effects as observed with other immunotherapies. Furthermore, the use of highly 
REFERENCES  11 
 
 
immunogenic target epitopes circumvents the limitations of the T cell repertoire 
directed against tumor-associated auto-antigens. The flexible design of ATPPs 
allows development of an off-the-shelf repertoire of immunoconjugates comprising 
immunogenic T cell epitopes encoded by highly prevalent pathogens and presented 
by various high frequency HLA allotypes, thereby providing a means for T cell 










Ziel dieser Doktorarbeit war die Evaluierung der Möglichkeit, immunogene, virale 
Peptide mittels tumorspezifischen Antikörpern in Krebszellen einzuschleusen, 
sodass diese durch virusspezifische, zytotoxische T Zellen erkannt und lysiert 
werden. Zu diesem Zweck wurden ATPP genannte (engl. antibody-targeted 
pathogen-derived peptides) Antikörper-Immunkonjugate hergestellt, indem 
immundominante, cysteinhaltige MHC-I Peptide aus dem Epstein-Barr oder 
Influenza A Virus über eine Disulfidbrücke an tumorspezifische Antikörper konjugiert 
wurden. Das Transmembranprotein CDCP1 (engl. CUB-domain-containing-protein-
1) wurde als Zielantigen ausgewählt, da es in mehreren Krebsarten überexprimiert 
wird und weil es sehr schnell internalisiert nach Antikörperbindung.  
Mittels Fluoreszenz-Resonanzenergietransfer (FRET)-basierter Bildgebung konnte 
gezeigt werden, dass die gekoppelten Peptide nach Bindung des ATPP Konjugats 
an das Antigen und folgender Internalisierung durch Reduktion der Disulfidbrücke in 
Endosomen freigesetzt werden. Dort binden die viralen Peptide an zelluläre MHC-I 
Moleküle. Im Folgenden werden diese Peptid-MHC Komplexe zur Zelloberfläche 
transportiert, wo sie von peptidspezifischen T Zellen erkannt werden können. Mittels 
Interferon-γ ELISA und ELISPOT wurde bewiesen, dass eine Behandlung mit ATPP 
zur Aktivierung von humanen, peptidspezifischen zytotoxischen T Zellen durch die 
entsprechenden Tumorzellen in vitro führt.  Des Weiteren waren sowohl in vitro 
expandierte als auch frisch isolierte T Zellen aus humanem Blut in der Lage, ATPP 
behandelte Krebszellen von verschiedenen Tumorindikationen antigenabhängig zu 
lysieren. Dies konnte für verschiedene Zielantigene (z.B. CD138), als auch mit 
mehreren Peptiden mit unterschiedlichen HLA-Restriktionen gezeigt werden. Mithilfe 
eines nicht spaltbaren Konjugats wurde zudem die Notwendigkeit der 
disulfidabhängigen Spaltung aufgezeigt. Die Verwendung eines verlängerten 
Peptids, welches ohne intrazelluläre Prozessierung nicht auf MHC-I Komplexe 
geladen werden kann, bewies außerdem, dass die in den Endosomen freigesetzten 
Peptide nicht in den klassischen Weg der MHC-I abhängigen Antigenprozessierung 
eintreten.  
Die in vivo Wirksamkeit der Immunkonjugate wurde anschließend im Tierversuch 
getestet. NOG Mäuse wurden subkutan mit der PD-L1 exprimierenden, humanen 
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Brustkrebszelllinie MDA-MB231 inokuliert und nach adoptivem Transfer von 
humanen peptidspezifischen T Zellen mit ATPP und αPD1 Antikörper behandelt, 
sobald die Tumore 70mm3 erreicht hatten. Die Kombinationstherapie erzielte eine 
deutliche, ca. 60%ige Inhibition des Tumorwachstums nach 3 Wochen Behandlung. 
Diese Resultate suggerieren ein großes Potential des hier vorgestellten Ansatzes 
der Krebsimmuntherapie, welcher darauf abzielt, Tumorzellen mit bereits 
existierenden, virusspezifischen T-Gedächtniszellen zu bekämpfen. Dieses Konzept 
schließt somit die Entstehung von autoimmun assoziierten Nebenwirkungen aus, da 
die Immunantwort – im Gegensatz zu bestehenden Immuntherapien – gegen ein 
exogenes, virales Antigen gerichtet ist, welches zudem eine höhere Immunogenität 
als körpereigene Tumorantigene aufweist. Durch die Entwicklung von ATPP 
Konjugaten, welche mehrere Peptide von verschiedenen Viren mit hoher 
Seroprävalenz enthalten, die zudem an häufig vorkommende HLA Moleküle binden, 
könnte dieser Ansatz dem Großteil der Patienten zugänglich gemacht werden. 
 
 





5.1. Hallmarks of cancer development 
Despite substantial advances in prevention, early diagnosis and therapy, as 
evidenced by a 23% drop in the cancer death rate from 1991 to 20121, cancer still 
remains one of the leading causes of death especially in developed countries1,2. In 
the United States about 1.7 million new cancer cases and 600,000 cancer-related 
deaths are assumed to be diagnosed in 20161, hence highlighting the need to further 
decipher the mechanisms of cancer formation and progression, in order to develop 
sophisticated treatment strategies. 
In the last decades numerous molecular mechanisms underlying cancer 
development have been unraveled, with the major hallmark being genomic 
mutations. Especially functional disruption of tumor suppressor genes or 
hyperactivation of oncogenes plays a major role for cellular transformation. 
Accumulation and manifestation of these genetic variations eventually lead to 
alterations in cellular physiology and metabolism and acquisition of the hallmarks of 
cancer, as postulated by Hanahan and Weinberg3,4.  
The most obvious property of cancer cells involves their capacity to proliferate 
infinitely. While normal cells require mitogenic growth signals in order to grow and 
divide, tumor cells exhibit reduced dependence on exogenous growth stimulation, 
which can be achieved by upregulating growth receptors (such as epidermal growth 
factor receptor, EGFR) and/or production of growth factors (also by the tumor 
stroma) for autocrine stimulation5-7. Most importantly, mutations in oncogenic 
signaling molecules such as Rat sarcoma viral oncogene homolog (Ras) allow 
mitogenic downstream signaling without external stimuli8,9. On the other hand, 
evasion from growth suppressive mechanisms, e.g. downregulation of tumor growth 
factor-β (TGFβ) receptors, relieves the homeostatic growth control and further 
enhances cancer proliferation and cell cycle progression10,11.  
An important safeguard mechanism to prevent propagation of transformed cells 
represents the induction of apoptosis. Different pathways have evolved to sense 
cellular abnormality, such as excess DNA damage, hypoxia or oncogene 
hyperactivation, in turn triggering cell death of transformed cells12,13. Hence, incipient 
cancer cells must acquire abilities to evade apoptosis induction. Several 
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mechanisms have been unraveled, including upregulation of anti-apoptotic factors 
(such as the B cell lymphoma proteins Bcl-2, Bcl-XL), functional loss of pro-apoptotic 
molecules or apoptotic signaling components, as well as mutations in sensors of 
cellular transformation (e.g. p53)12,14. 
Having acquired growth signal autonomy, evasion/unresponsiveness to growth 
inhibitors and resistance to apoptosis, there is still another hurdle to take before 
tumor cells can grow infinitely. As revealed by Hayflick in 1997, cells have a limited 
replicative potential in culture15. At some point, accumulation of cellular stress due to 
reactive oxygen species (ROS) or oncogene activation leads to a state termed 
senescence that is induced by the activation of tumor suppressor genes, such as 
retinoblastoma protein (pRB) or p5316,17. After inactivation of these genes, cells will 
eventually progress until reaching the state of crisis, which ultimately limits their 
replicative potential18,19. This state bases on the progressive shortening of telomeres 
upon DNA replication until the point where the chromosomes end20. Unprotected 
telomeres eventually result in chromosomal fusions of their ends, in turn yielding 
karyotypic disorder and cell death. However, by acquiring expression of the gene 
telomerase, which is generally limited to stem cells, cancer cells counteract telomere 
shortening and prevent crisis induction21,22. 
As oxygen and nutrients supplied by the blood are essential for cell function and 
survival, neoplasms have to additionally acquire angiogenic ability, rendering it 
another important hallmark of cancer. Along this line, tumor cells trigger the release 
of pro-angiogenic factors (e.g. vascular endothelial growth factor, VEGF or fibroblast 
growth factor, FGF) within the microenvironment by either expressing them or 
inducing their release from stromal cells, while simultaneously downregulating 
inhibitors of angiogenesis such as thrombospondin-123,24.  
The last and in most patients eventually lethal characteristic of cancer cells is their 
capability to invade the surrounding tissue and disseminate via the blood stream to 
generate metastasis in other organs. Enabling metastatic capacity is accompanied 
by the so-called epithelial-mesenchymal transition (EMT), which involves production 
of extracellular matrix proteases, loss of adhesion molecules such as E-cadherin and 
altered integrin expression, in turn allowing intravasation into the blood stream, traffic 
to distant sites, extravasation into the tissue and formation of new tumor tissue25,26.  
Besides the six mentioned and well-accepted hallmarks, four additional 
characteristics of cancer have been proposed and reviewed by Hanahan and 
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Weinberg4.  In this respect, especially the finding that tumors employ mechanisms to 
evade recognition and/or destruction by the immune system has fostered the 
development of a novel, promising concept for the treatment of cancer: cancer 
immunotherapy. 
 
5.2. Cancer immunosurveillance and immune tolerance 
Although chronic inflammation is known as a risk factor for cancer development27,28, 
immune cells also play a major role in the elimination of incipient cancer cells, as 
defined in the theory of cancer immunosurveillance29-31.  
In the late 1970s, Boon and colleagues have already proven the existence of 
antigens that can trigger immune rejection of mutagen-treated teratocarcinomas in 
C57BL/6 mice32-34. More detailed insights into the mechanisms of cancer 
immunosurveillance came from studies using mice that were genetically engineered 
to lack certain components of the immune system. For instance, abrogation of 
interferon-γ (IFNγ) signaling35,36 or perforin37,38 resulted in increased incidence of 
carcinogen-induced tumors. While IFNγ can upregulate major histocompatibility 
complexes (MHCs) on cancer cells36, promote CD4+ Th1 T helper cell and CD8+ 
cytotoxic T cell generation as well as trigger cytocidal macrophage activity39, perforin 
acts as an effector molecule in the cytolytic granules of natural killer (NK) and 
cytotoxic T cells40,41.  
On the cellular basis, the use of mice lacking the recombinase activating gene 
(RAG)-1 or RAG-2 revealed a major implication of lymphocytes in the prevention of 
sarcoma outgrowth following carcinogen encounter36,42. Since RAG-1 and -2 are 
indispensable mediators of somatic antigen receptor rearrangement in lymphocytes, 
RAG-deficient mice are unable to generate peripheral B cells, NKT cells as well as 
αβ or γδ T cells43. Follow up studies subsequently identified that αβ, γδ T cells44,45, 
NKT, as well as NK cells42 do all exert critical antitumor functions. While NK cells can 
detect tumor cells by a lack of MHC molecules and/or expression of stress-
associated NKG2D ligands46-48, NKT cells recognize glycolipid antigens presented 
by CD1d and mainly act by producing cytokines to promote differentiation and 
activation of surrounding immune cells49. In contrast, tumor cell recognition by γδ T 
cells has been attributed to NKG2D receptor as well as γδ T cell receptor (TCR) 
engagement, the latter of which is known to bind phospho-antigens50. The most 
investigated cell type, however, are αβ T cells, which recognize tumor antigen-
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derived peptides, presented in the context of MHC. Initial human T cell responses 
against tumor cells could be observed in vitro by co-culturing patient-derived 
melanoma cell lines with autologous lymphocytes51. A few years later, the first 
human tumor antigen recognized by T cells could be identified in melanoma: MAGE-
A1 (Melanoma associated antigen A1, aka MZ2-E)52. 
However, as cancers still arise, the process of immunosurveillance is not 100% 
efficient. The failure of this safeguard mechanism derives from immunological 
tolerance as a result of an initial lack of immunogenic antigens and the proper pro-
inflammatory conditions. For instance, the emergence of so-called driver mutations 
in oncogenes (e.g. K-Ras) and tumor suppressor genes (e.g. p53) often comprise 
point mutations that suffice to initiate cellular transformation9,53-55, while providing few 
possibilities for immunogenicity. In addition, an inflammatory response will only be 
initiated upon tumor growth when tumor necrosis and tissue invasion accompanied 
by destruction of the basement membrane promote the release of danger signals. 
For instance, released intracellular molecules, such as adenosine triphosphate 
(ATP), high mobility group box 1 (HMGB1), S100 or heat shock proteins serve as 
danger-associated molecular patterns (DAMPs) to activate pattern recognition 
receptors (PRRs) on resident immune cells, in turn initiating the inflammatory 
response56. Nevertheless, the lack of potent inflammatory stimuli, such as pathogen-
associated molecular patterns (PAMPs) has led to the term “sterile inflammation” in 
this context and explains why a productive anti-tumor response may still not arise.  
As mentioned, the antigen repertoire of cancer cells has also major implications for 
immune tolerance. Recent advances in the development of sophisticated screening 
technologies, such as mass-spectrometry, whole exome or RNA sequencing as well 
as bioinformatical epitope prediction and peptide-MHC binding algorithms have 
allowed the investigation of antigen epitopes presented by cancer cells and those 
specifically recognized by tumor infiltrating lymphocytes (TILs)57,58. Application of 
these technologies has revealed that primarily mutation-derived neo-epitopes trigger 
T cell-mediated cancer eradication and that these neo-antigen-specific T cells are 
exploited by cancer immunotherapies that rely on the endogenous T cell pool59,60. 
However, a high frequency of non-synonymous mutations and T cell neo-epitopes 
does not necessarily imply a productive T cell response. As evidenced in a recent 
study by Stronen et al. only 2 out of 126 predicted epitopes were recognized by TILs 
in melanoma patients61. Nevertheless, the authors showed that the naïve T cell 
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repertoire from healthy blood donors could mount an antigen-specific response 
against several of these epitopes, suggesting ineffective priming and/or tolerization 
of these T cells in the patient. Hence, there are several aspects of immune tolerance 
that counteract immune effector responses. While central tolerance relies on the 
absence of antigen-specific T cells due to thymic deletion of self-reactivity, peripheral 
tolerance results from a lack of co-stimulatory signals and tumor-mediated 
immunosuppression as explained further below. 
 
5.3. The anti-cancer immune response, immunoediting and immune escape 
The current understanding of anti-cancer immune responses involves virtually all cell 
types of the human immune system. In detail, an effective tumoricidal response is 
initiated by innate immune cells, which are activated by ligands in the tumor micro-
environment, including type I IFNs, DAMPs like ATP or HMGB1, as well as stress-
associated molecules like NKG2D ligands62,63. Activated macrophages or NK cells 
subsequently release pro-inflammatory cytokines and chemokines, which attract and 
favor the development of other immune cells, such as dendritic cells (DCs). After 
antigen uptake in the tumor DCs migrate to the lymph node, where they present 
processed antigens to CD4+ T helper (Th) cells64. Upon engagement of their cognate 
TCRs and co-stimulation by DC-expressed CD80 and CD86 molecules CD4+ T cells 
proliferate and differentiate into Th1 cells under the influence of DC-derived 
cytokines, such as Interleukin-12 (IL-12) and type I IFNs. Following activation, CD4+ 
T cells upregulate CD40 ligand (CD40L) expression65, in turn stimulating surrounding 
antigen-presenting cells (APCs) and promoting DC cross-presentation of internalized 
antigens on MHC class I molecules66,67. Interaction of CD8+ T cells with their cognate 
MHC class I-peptide complex subsequently triggers the development and expansion 
of CD8+ cytotoxic T lymphocytes (CTLs), which migrate to the tumor and exert their 
cytotoxic functions when encountering their target antigen.  
Clinical evidence for an ongoing anti-cancer immune response in established tumors 
initially came from observations that the abundance of TILs correlates with good 
prognosis in melanoma patients68,69. Up to date numerous studies have attributed a 
prognostic value to TILs in a variety of cancers, including colorectal70, ovarian71 and 
hepatocellular carcinoma72. Detailed, systemical analysis further revealed that the 
cellular composition of the lymphocytic immune infiltrate decisively determines the 
outcome, as reviewed by Fridman and colleagues73. For instance, the presence of 
REFERENCES  19 
 
 
Th1 cells or antigen-experienced (CD45RO+) CD8+ T cells is favorable74,75, while the 
abundance of regulatory T cells (Tregs)76,77 correlates with bad prognosis. The 
impact of Th2 and Th17 cells even depends on the cancer type73,78. 
The potential of the human immune system to combat cancer has further been 
highlighted by clinical epidemiology data. In detail, transplant recipients receiving 
immune-suppressive drugs exhibited higher tumor incidences in a variety of 
studies79-82. As evidenced in recent years, immunosuppressed individuals especially 
reveal higher susceptibility to cancers that exhibit a high number of somatic 
mutations (such as melanoma)83 and hence are likely to be recognized by an intact 
immune system. 
In contrast to its protective role in eliminating transformed cells, the immune system 
can also foster the generation of cancer cells with low immunogenicity. When the 
immune system continuously deletes nascent tumor cells, only those acquiring 
immunoevasive mechanisms can survive. First hints for this process came from 
tumor transplantation studies in immunocompetent versus immuno-compromised 
mice. While tumors from wild type (wt) mice grew equally well in immunocompetent 
or -compromised animals, tumors derived from RAG-2-/- or Perforin-/- animals only 
exhibited comparable growth kinetics in their syngeneic immunocompromised 
counterparts, while most of the tumors were rejected upon transplantation into wt 
mice36,37. From these experiments the authors concluded that tumors of wt mice had 
escaped immune recognition during the elimination phase and hence could not be 
recognized by the immune system of the syngeneic recipient. In contrast, tumors 
from immunodeficient mice did not experience shaping by the immune system due to 
the absence of immunological selection pressure and thus were unable to trigger 
tumor formation after transplantation into immunocompetent animals. This 
phenomenon of the immune system favoring the selection and outgrowth of escape 
variants with reduced immunogenicity has been called cancer immunoediting and 
has been extensively described and reviewed by Schreiber and colleagues30,31,84,85. 
 
5.4. Mechanisms of cancer immune escape 
The emergence of immune escape variants in the process of cancer immunoediting 
can be considered an evolution-based scenario with a Darwinian-like selection 
process for poorly immunogenic tumor cells. Due to the huge heterogeneity of 
tumors and even the cellular heterogeneity within tumors, the mechanisms of 
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immune escape are very divers and success is determined by the accumulation of 
multiple immunoevasive features.   
As mentioned, reducing immunogenicity represents a potent strategy to prevent an 
effector immune response. In this regard, several mechanisms have been explored. 
These include inhibiting antigen presentation (e.g. by downregulation of MHC 
molecules)86, preventing antigen generation (e.g. by functional loss of proteins 
implicated in the antigen processing pathway, such as proteasome subunits LMP2/7 
or the peptide transporter TAP)87,88, or simply deletion of immunogenic antigens89.  
On the other hand, immune recognition does not necessary imply tumor cell killing, 
as tumor cells have also evolved mechanisms to prevent immune-mediated cell 
death. By upregulating anti-apoptotic proteins, such as cFLIP, XIAP or BCL-2, 
cancer cells directly interfere with the apoptosis-inducing effector mechanisms of 
immune cells, triggered by CD95 (aka FAS) or TRAIL receptor engagement90-92.  
While the above-mentioned strategies imply a rather passive form of immune 
escape, tumor cells can also directly inhibit the action of immune cells. Along this line 
surface expression of ligands, such as programmed death-ligand 1 (PD-L1)93, HLA-
G94 or HLA-E95 as well as CD95 ligand (CD95L)96, interacts with T cell-associated 
receptors in order to counteract activation or induce apoptosis. Besides, metabolic 
enzymes in tumor cells such as indolamine-2,3-dioxygenase (IDO)97,98, arginase99,100 
or inducible nitric oxide synthetase (iNOS)101 can exert a variety of T cell suppressive 
functions102. Specifically, by catabolizing it into kyurenine IDO deprives tryptophan, 
which leads to downregulation of the CD3 zeta chain103 as well as T cell apoptosis 
and impaired effector T cell differentiation104. Nitric oxide (NO) produced by iNOS, in 
turn can nitrate T cell receptors thereby blocking signal transduction105. In addition, 
tumor cells do also inhibit innate immune functions. For instance, shedding of soluble 
NKG2D ligands MICA or MICB impairs NK cell function106, while sterol metabolites 
can block DC migration to the lymph nodes by suppressing chemokine receptor 7 
(CCR7) expression107. 
Alternatively, tumor cells may promote the generation of an immunosuppressive 
microenvironment, as initially suggested by a study showing that mice bearing late-
stage tumors which are not eliminated by the immune system exhibit functional 
systemic T cell responses108. The emergence of such an environment is fostered by 
the release of immunosuppressive factors which – besides directly inhibiting immune 
cells – trigger the differentiation of immunosuppressive cell types. As an example, 
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TGFβ induces the conversion of effector T cells into Tregs, which in turn inhibit 
effector T cell function by various mechanisms including IL-2 deprivation, production 
of the immunosuppressive cytokine IL-10109 or the expression of PD-L1 or cytotoxic 
T lymphocyte-associated protein-4 (CTLA-4) molecules110. PD-L1 interacts with its 
receptor PD1 that is upregulated on T cells upon activation and IFNγ encounter. PD1 
co-localizes with TCR microclusters and following ligand engagement recruits 
phosphatases such as SHP2 that dephosphorylate downstream signaling molecules 
like CD3-zeta or Zap70, thereby inhibiting T cell activation111. On the other hand, 
CTLA-4 is though to primarily exert its suppressive function by competing with CD28 
for CD80 and CD86 binding, hence preventing their interaction and dampening co-
stimulatory signaling112. Initially, CTLA-4 was thought to additionally downregulate 
CD80/CD86 expression on DCs113,114, although recent work suggests no implication 
in this respect115. While Tregs utilize these two molecules to prevent autoimmunity 
under physiological conditions116, they hamper antigen-specific CD8+ T cell 
responses in the tumor microenvironment, thereby preventing tumor rejection117-119.  
Besides Tregs, the production and elaboration of factors such as granulocyte-
macrophage colony-stimulating factor (GM-CSF), vascular endothelial growth factor 
(VEGF), IL-1β and prostaglandin E2 (PGE2) induces the differentiation and 
expansion of so-called myeloid-derived suppressor cells (MDSCs), which also 
hamper anti-tumor immunity. Initially, these and other factors like platelet-derived 
growth factor (PDGF) or epidermal growth factor (EGF) derive from M2 
macrophages, which are implicated in wound healing and hence the first to migrate 
to the inflammatory tumor microenvironment120. These tumor-associated 
macrophages (TAMs) have been shown to support tumor progression by promoting 
angiogenesis, invasion as well as metastasis121,122. During the following phase of the 
anti-cancer immune response, myeloid precursor cells enter the tumor, in order to 
advance the local immune response. Nevertheless, chronic inflammation, hypoxia as 
well as tumor-derived factors within the microenvironment perturb the differentiation 
and maturation process, in turn producing highly immunosuppressive MDSCs123. As 
seen for many cancer-associated cells, MDSCs closely interact with TAMs by 
generating positive feedback loops, which – in turn – enhance immunosuppression: 
MDSC-derived IL-10 blocks IL-12 production in TAMs. Resulting high IL-10 and low 
IL-12 levels promote differentiation of type-2 T helper (Th2) cells, which secrete IL-4 
that again triggers M2 polarization of macrophages.  
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Clinical reports have revealed that elevated MDSC levels correlate with cancer 
malignancy, owing to the multiple mechanisms MDSCs employ to manipulate tumor, 
endothelial as well as immune cells124. For example TAM- or MDSC-derived VEGF 
and IL-10 induce CD95L in tumor endothelial cells to trigger apoptosis of CD8+ 
effector T cells125. In addition, MDSCs secrete CCR5 ligands and TGFβ/IL-10 to 
recruit and stimulate differentiation of Tregs, respectively126,127. As explained, Tregs 
express CTLA-4, which interferes with CD80 and CD86 availability on DCs113,114. As 
a consequence, tumor antigen-specific T cells experience a lack in co-stimulatory 
signals required for CD28 engagement, resulting in anergy. In addition, interaction 
with Tregs can prompt DCs to exert tolerogenic effects through CTLA-4-dependent 
production of IL-10 and IDO128,129. Besides, MDSCs also produce high levels of 
iNOS and IDO on their own, the action of which has already been explained above. 
Nitrating or nitrosylating amino acids within TCRs renders T cells unresponsive to 
antigenic stimulation130. In general, it seems that reactive oxygen species (ROS) 
have a pivotal role in the suppressive activity of MDSCs, as inhibition of ROS 
generation in MDSCs isolated from murine and human tumors completely abrogated 
the inhibitory effects in vitro131,132. Though, recent data suggest that physiologic 
concentrations of macrophage-derived NO promotes T cell infiltration into the 
tumor133. 
Thus tumors exert and induce a plethora of immunosuppressive mechanisms, 
including the generation of an intensely cooperating, highly complicated network of 
immunosuppressive immune cells that blocks immune recognition and allows cancer 
formation as well as progression. 
 
5.5. Recent approaches in cancer immunotherapy 
The potential of exploiting immune cells for cancer therapy has been decisively 
strengthened during the last decade. In particular, the exploration and advanced 
understanding of the numerous mechanisms of cancer immunosurveillance, 
immunoediting and immunosuppression has allowed and inspired the development 
of innovative therapeutics. Along this line, cytokine therapy including the 
administration of IL-2134 or IFNα135 were administered partially successfully. 
Promising results were also achieved with small molecule inhibitors trying to block 
IDO or iNOS function102,136,137. Yet, these approaches lacked cancer-specific 
targeting. Enhanced cancer-specificity was achieved by the use of monoclonal 
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antibodies targeting tumor antigens, such as CD20 (rituximab) in leukemia138,139. 
Besides blocking receptor signaling, these antibodies exploit the function of immune 
cells such as NK cells or neutrophils by triggering Fc-mediated antibody-dependent 
cellular cytotoxicity (ADCC) or by initiating complement-dependent cellular 
cytotoxicity (CDC). 
Due to its huge diversity and capacity to specifically respond to arising mutations, the 
T cell repertoire represents a powerful natural defense mechanism against cancer 
formation and its heterogeneity. As a result of co-evolution, many immunoevasive 
mechanisms of tumors ultimately aim at interfering with tumor antigen-specific T cell 
responses and hence restoring, boosting or initiating their functionality seems 
desirable. In this context, the detection of graft-versus-leukemia effects after 
allogeneic hematopoietic stem cell transplantation can be considered one of the first 
successful approaches of exploiting T cells for cancer treatment140. Further on, the 
discovery of spontaneous T cell responses against tumor antigens in human patients 
has created the basis for T cell-based cancer immunotherapies141,142. Up to date, 
different approaches have already successfully attempted to amplify or induce the 
anti-cancer immune response, e.g. by adoptive transfer of ex vivo expanded TILs or 
by tumor vaccination therapy59. For instance, Carreno and colleagues have recently 
generated a dendritic cell vaccine by loading DCs with neo-antigen peptides, which 
efficiently broadened the repertoire of tumor antigen-specific T cells in melanoma143. 
In recent years, it has become clear that that especially cancers with high mutational 
load (such as melanoma) are immunogenic and counteract immune destruction by 
the generation of an immunosuppressive microenvironment83,144. In this respect, 
targeting of immune checkpoint pathways has emerged as a potent approach to 
revert immunosuppression and to restore the tumor-specific T cell response. 
Immune checkpoints exert either co-stimulatory or co-inhibitory functions and serve 
to regulate the amplitude and duration of immune responses145. Under physiological 
conditions these molecules hence function to restrain immune responses and 
maintain self-tolerance, e.g. by preventing excess pro-inflammatory damage to the 
host146. As already explained, tumors exploit co-inhibitory molecules, such as PD-L1 
or CTLA-4 expressed either on tumor or immunosuppressive immune cells. As can 
be inferred from the above-mentioned functions, CTLA-4 primarily dampens the 
priming of naïve and memory T cells upon APC interaction147, while PD1 
engagement counteracts TCR signaling, thereby preventing proliferation as well as 
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cytotoxic function and ultimately resulting in T cell exhaustion and apoptosis148-150. In 
addition, stimulation of PD1 on macrophages has been shown to inhibit T cell 
responses by promoting IL-10 release in HIV-infected patients151. In recent years, 
several clinical studies have proven the therapeutic efficacy of checkpoint blockade 
for cancer immunotherapy60. Along this line, CTLA-4-blocking antibody ipilimumab 
was the first checkpoint inhibitor demonstrating survival benefit in a randomized trial 
of advanced melanoma152. Besides blocking intermolecular interactions of the CTLA-
4 molecule, ipilimumab additionally triggers ADCC-mediated clearance of CTLA-4+ 
cells, such as Tregs153,154. Similarly, antibodies blocking PD1 (nivolumab, 
pembrolizumab,) or PD-L1 (atezolizumab) have shown striking efficacy in clinical 
studies and have recently been approved by the Food and Drug Administration 
(FDA) as first line treatment for melanoma, bladder cancer, non-small-cell lung 
cancer (NSCLC) and Hodgkin lymphoma155-157. Although PD1 and CTLA-4 
antagonists have been most intensively investigated to date, further inhibitory 
receptors such as TIM3 and LAG3 are being evaluated146,158. In addition, agonistic 
antibodies and fusion molecules targeting co-stimulatory T cell checkpoint receptors 
of the tumor necrosis factor (TNF) superfamily (e.g. OX40, CD40L, 4-1BB, GITR) are 
currently being assessed in clinical trials145. Promising data was achieved with an 
OX40 agonistic antibody, which induced regression of metastatic lesions in 12 out of 
30 melanoma patients159. Moreover, 4-1BB agonistic treatment resulted in partial 
responses and stable disease in patients with renal cell carcinoma, ovarian cancer, 
prostate cancer and melanoma160,161. Based on these promising data and the known 
interplay between multiple immunosuppressive pathways within the tumor 
microenvironment, combinatorial targeting of different co-stimulatory and/or                
-inhibitory immune checkpoints seems reasonable. In this respect, combination 
therapy of ipilimumab and nivolumab exhibited 53% increased efficacy compared to 
monotherapy in a phase I trial of advanced melanoma162. Besides, pre-clinical 
mouse studies confirmed that combining PD1 blockade with either 4-1BB or OX40 
antagonists results in an improved anti-cancer immune response163,164.  
Accumulating data suggests that targeting immune checkpoints is favorable in 
tumors, where a tumoricidal T cell response is prevented by an immunosuppressive 
microenvironment165,166. Besides melanoma, these particularly include cancers of the 
lung and bladder, which carry a high number of somatic mutations and hence 
provide a basis for the production of immunogenic antigens83. This hypothesis was 
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further strengthened by a genome-wide neo-epitope analysis in melanoma patients, 
where responsiveness to ipilimumab therapy could be correlated to mutational 
load167. Therefore, other immunotherapeutic strategies have been applied for the 
treatment of cancers with a low to moderate mutational background. Along this line, 
bispecific T cell engagers (BiTEs) and chimeric antigen receptor T cells (CAR-Ts) 
aim at triggering de novo T cell responses against cancer. BiTEs are bispecific 
antibody molecules carrying two different target moieties: one targets a tumor 
specific antigen and the other binds the CD3 part of the TCR in an agonistic manner. 
Hence, BiTEs function by redirecting T cells against tumor cells independently from 
their specificity. BiTEs have already revealed profound efficacy in hematological 
malignancies, whereas exhibiting limited potency in solid tumors. So far, an epithelial 
cell adhesion molecule (EpCAM)-targeting (catumaxomab), as well as a CD19-
targeting BiTE (blinatomumab) have shown efficacy in several cancer types and 
have been approved by the FDA for therapy of malignant ascites and refractory B 
cell acute lymphoblastic leukemia (B-ALL), respectively168-173. Besides, a BiTE 
against the carcinoembryonic antigen (CEA) expressed in various solid tumors is 
being evaluated in phase I clinical trials174.   
On the other hand, CAR-Ts represent T cells that have been genetically engineered 
to express a chimeric antigen receptor, which consists of an extracellular single-
chain variable fragment (scFv) binding the target and intracellular signaling domains 
of the TCR. Binding of the scFv to the tumor antigen induces TCR downstream 
signaling, in turn triggering T cell activation and cytotoxic activity. Recently, next 
generation CAR-Ts have been generated by including intracellular signaling domains 
from molecules implicated in co-stimulation, such as CD28, OX40 or 4-1BB175. CAR-
Ts have proven striking efficacies in hematological cancers and adoptive transfer of 
the FDA-approved CART19 targeting the CD19 receptor has achieved 90% 
complete remission rates in patients with refractory B-ALL176,177. In addition, 
targeting the NY-ESO-1 antigen generated durable responses in multiple myeloma 
and synovial cell sarcoma patients178,179. In pre-clinical models, a mesothelin-
targeting CAR-T was applied to eradicate human mesothelioma lesions180.  
Nevertheless, despite remarkable efficacy and sophisticated engineering 
technologies, immunotherapies have always entailed risks for immune-related side 
effects. While both BiTEs and CAR-Ts have been struggling with unexpected 
cytokine storm or tumor lysis syndrome, major concerns about CAR-T therapy 
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additionally derive from the possibility of insertional mutagenesis leading to T cell 
lymphoma176,181-184.  
 
5.6. Aim of the study 
In order to overcome existing immune tolerance against endogenous tumor antigens, 
we employed a novel strategy of cancer immunotherapy by targeting virus-derived 
peptides to tumor cells, thereby exploiting the high affinity T cell repertoire. Our 
approach uses antibody-targeted pathogen-derived peptides (ATPPs) that deliver 
virus-derived, mature MHC class I peptides, which are bound via a disulfide bond to 
a tumor antigen-specific antibody.  
In this study we primarily focused on CUB domain-containing protein 1 (CDCP1, aka 
Trask, CD318) as proof of concept target. The integral membrane protein CDCP1 
negatively regulates cell adhesion upon Src-mediated phosphorylation by interacting 
with β1-integrin and signaling via PI3K/Akt pathway185. CDCP1 is highly expressed 
in various cancer types (including breast, kidney, lung, pancreas) and its 
upregulation correlates with increased relapse rate, metastasis and poor 
prognosis186-189. Although it is also low to moderately expressed in various healthy 
tissues, thereby probably not representing the antigen of choice for clinical 
translation of the ATPP concept, choosing CDCP1 as target allowed testing of the 
ATPP approach in multiple cancer cell lines. Moreover, a previous study has already 
proven CDCP1 internalization upon binding of the utilized antibody190, which 
represents a prerequisite for ATPP functionality. 
The postulated mode of action of ATPP immunoconjugates is depicted in Figure 5.1. 
After binding of ATPPs to the target antigen, the antigen-conjugate complex is 
internalized into the endocytic compartment. Given the findings from Yang et al.191 
that disulfide reduction efficiently occurs in endosomes, the peptides are 
subsequently released from the antibody. In general, external antigens enter the 
MHC class II processing and presentation pathway, while MHC-I molecules are 
loaded with endogenous peptides192. Nevertheless, ATPPs deliver mature 9-mers 
that can readily bind to the MHC-I molecule. By additionally exploiting the fact that 
recycling of MHC molecules to the cell surface – despite being dominant in DCs – 
also occurs under normal conditions193,194, the ATPP approach aims at generating 
class I MHC-peptide complexes on the cell surface. Accordingly, peptide-specific T 
cells encounter a viral antigen, which prevents the possibility of autoimmune side 
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effects and additionally suggests higher immunogenicity than targeting a tumor 
antigen. By choosing immunodominant peptides binding to high frequency HLA 
allotypes (such as HLA-A1 or HLA-A2) and deriving from viruses that have high 
seroprevalence (e.g. Epstein-Barr virus or Influenza) this approach is supposed to 
ensure treatment of the vast majority if not the entire patient population.  
The present study aimed at investigating the functionality and putative efficacy of 




Figure 5.1 Proposed model for the mode of action of ATPP immunoconjugates. 
A: Binding of ATPP immunoconjugates to target antigen. B: Internalization of ATPP into endosomal 
compartment. C: Release of T cell response eliciting peptide from the immunoconjugate in the 
endosomal compartment.  D: Release of self-peptides and loading of recycling MHC class I molecules 
with delivered virus-derived peptides. E: Routing of viral peptide-loaded MHC class I complexes to 
target cell surface. F: Recognition of viral peptide-loaded MHC class I complexes on target cell 
surface by peptide-specific CD8+ T cells, in turn inducing T cell activation and target cell lysis (death).  




6. Materials and Methods 
6.1. Materials   
6.1.1. Laboratory Devices 
 
Incubator BBD6220 Thermo Scientific Heraeus 
Vi-Cell XR Cell Viability Analyzer Beckman Coulter Biomedical 
Centrifuge Multifuge 4 KR Thermo Scientific Heraeus 
Centrifuge Multifuge 3SR+ Thermo Scientific Heraeus 
Centrifuge Rotanta 460 R Hettich Lab Technology 
Herasafe KS12 cabinet Thermo Scientific 
Laboratory scale Sartorius 
FACS Canto II analyzer BD Biosciences 
xCELLigence RTCA SP ACEA Biosciences 
Pipetboy acu 2 INTEGRA Biosciences 
2.5, 10, 100, 200, 1000, 5000 μL pipettes Eppendorf 
300, 1000μL electric multi-channel pipettes BioHit 
Irradiation device GSR CI GSM GmbH 
Plate Reader Infinite 200Pro TECAN Group Ltd. 
ELISA plate washer MicroTek AWS BioTek Instruments GmbH 
Water bath Julabo 5M Julabo 
Leica SP8 microscope Leica Instruments GmbH 
ImmunoSpot S5 Analyzer Cellular Technology Ltd. 
RM5 roller mixer CAT 
 
 





Cell culture flasks (T25, T75, T175) Greiner 
Low adherence cell culture flasks Greiner 
G-Rex10 Wilson Wolf  
G-Rex100 Wilson Wolf 
6 / 12 / 24 / 48 / 96-well plates, flat bottom Greiner 
96-well plates, u-bottom  Greiner 
96-well plates, v-bottom (PE) Greiner 
E-Plates 96-well ACEA Biosciences 
0.5 / 1.5 / 2.0 mL Eppendorf tubes Eppendorf 
50 / 15 mL Falcon tubes Greiner 
250mL centrifugation tubes Corning 
2 / 5 / 10 / 25 / 50 mL pipet boy tips Greiner 
FACS tubes 5mL BD Biosciences 
Pipette tips Eppendorf 




6.1.3. Cell culture media and reagents 
 
RPMI 1640 Gibco by Life technologies 
CTS AIM-V medium Gibco by Life technologies 
DMEM PAN Biotech 
McCoy´s 5A medium PAN Biotech 
L-Glutamine, 100x, 200mM Gibco by Life technologies 
NEAAs, 100x (non-essential amino acids) Gibco by Life technologies 
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Sodium pyruvate, 100mM Gibco by Life technologies 
FBS (fetal bovine serum) heat-inactivated Gibco by Life technologies 
Human serum (from human male AB  
plasma) 
Sigma Aldrich 
2-mercaptoethanol, 50mM Gibco by Life technologies 
DPBS PAN Biotech 
Accutase solution Sigma Aldrich 
Penicillin-Streptomycin, 500x Roche Diagnostics GmbH 
DMSO (Dimethyl sulfoxide) Sigma Aldrich 
HEPES (2-[4-(2-hydroxyethyl)piperazin- 
              1- yl]ethanesulfonic acid) 
Gibco by Life technologies 
IL-15, human recombinant R&D Systems 
sIL-15Ra R&D Systems 
 
 
6.1.4. Antibodies for flow cytometry 
 
6.1.4.1. Primary antibodies (against human antigens) 
Target Clone Conjugate Source Isotype Manufacturer 
CD3 SK7 PE-Cy7 Mouse IgG1, κ BioLegend 
CD3 SK7 FITC Mouse IgG1, κ BioLegend 
CD4 OKT4 PE Mouse IgG2b, κ BioLegend 
CD8 HIT8a FITC Mouse IgG1, κ BioLegend 
CD8 HIT8a APC-Cy7 Mouse IgG1, κ BioLegend 
CD45 HI30 PerCP-
Cy5.5 
Mouse IgG1, κ BioLegend 
CD45 HI30 PE Mouse IgG1, κ BioLegend 
CD45RO UCHL1 PE Mouse IgG2a, κ BioLegend 
CD138 DL101 APC Mouse IgG1, κ BioLegend 
CD138 MI15 APC Mouse IgG1, κ BioLegend 
CD197 
(CCR7) 
G043H7 PE-Cy7 Mouse IgG2a, κ BioLegend 
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CD274      
(PD-L1) 
29E.2A3 APC Mouse IgG2b, κ BioLegend 
CD279     
(PD1) 
EH12.2H7 PE Mouse IgG1, κ BioLegend 
CD318 
(CDCP1) 
CUB1 PE Mouse IgG2b, κ BioLegend 
HLA-A1/36 8.L.104 Biotin Mouse IgM Abcam 
HLA-
A1/11/26 
8.L.101 - Mouse IgM Abcam 
HLA-A2 BB7.2 APC Mouse IgG2b, κ BioLegend 
 
 
6.1.4.2. Isotype control antibodies 
Isotype Clone Conjugate Source Manufacturer 
IgG2b, κ MPC-11 PE Mouse BioLegend 
IgG2b, κ MPC-11 APC Mouse BioLegend 
IgG1, κ MOPC-21 FITC Mouse BioLegend 
IgG1, κ MOPC-21 APC Mouse BioLegend 
IgM MM-30 - Mouse BioLegend 




6.1.4.3. Secondary antibodies 
Target Isotype Conjugate Source Manufacturer 
Mouse IgM F(ab’)2 FITC goat Life technologies 
Biotin 
(Streptavidin) 
- PE - BioLegend 
Human IgG (H+L) polyclonal Alexa 488 goat Life technologies 




6.1.4.4. Peptide-MHC pentamers (all from ProImmune) 
 Peptide sequence  Epitope origin HLA allele Conjugate Order # 
 CLGGLLTMV  EBV, LMP-2  426-434  A*02:01  APC  F042 
 GLCTLVAML  EBV, BMLF1 259-276  A*02:01  APC  F001 
 CTELKLSDY  Influenza A, NP 44-52  A*01:01  APC  F076 
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6.1.5. Reagents for FACS and microscopic imaging 
  
DAPI (4’,6-diamidin-2-phenylindol) Roche Diagnostics GmbH 
TruStain fcX™, human BioLegend 
TruStain fcX™ (anti-mouse CD16/32 Ab) BioLegend 
EDTA, 0.5M Gibco by Life technologies 
PKH26 Sigma Aldrich 
CMFDA Life technologies 
Culture-Insert 2 Well in µ-Dish 35 mm  
(# 81176) 
Ibidi  
Collagen type I Sigma Aldrich 
Alexa Fluor 647 conjugated αIgG (H+L)  
antibody 
Life technologies 




6.1.6. Reagents for ELISA, ELSPOT and LDH assay 
 
96-well MaxiSorp® plates Nunc 
Tween®20 Merck Millipore 
10x PBS, premixed buffer Roche Diagnostics GmbH 
Bovine serum albumin (BSA), 7.5% Sigma Aldrich 
Normal goat serum (NGS) R&D Systems 
αHLA-ABC antibody (clone W6/32) BioLegend 
BM Blue POD Substrate solution Roche Diagnostics GmbH 
Sulfuric acid (H2SO4) Merck 
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6.1.7. Ready to use kits 
  
Leucosep tubes Greiner 
RosetteSep RosetteSep™ Human CD8+ T  
Cell Enrichment Cocktail 
Stem Cell technologies 
Human IFN-γ ELISpot PRO kit  
(#3420-2APT) 
Mabtech 
Human IFN-gamma DuoSet ELISA kit  
(#DY285) 
R&D Systems 
Cytotoxicity Detection Kit (LDH) Roche Diagnostics GmbH 
  
 
6.1.8. Animals and in vivo equipment 
 
NOG CIEA mice Taconic Biosciences 
Cages Tecniplast 
Drink Bottle Tecniplast 
Bedding Ssniff 
Pelleted standard diet ProvimiKliba AG 
Electric shaver Harotec 
Caliper Mitutoyo Messgeräte 
Surgical instruments B. Braun Melsungen 
Isoflurane Vaporizer Eickenmeyer Medizintechnik 
Isofluran CP (Isoflurane) CP-Pharma 
27G needles STERICAN B. Braun Melsungen 











6.1.9. Reagents and consumables for processing of tissue samples 
 
DNase I Roche Diagnostics GmbH 
Collagenase IV Sigma Aldrich 
Dispase II Roche Diagnostics GmbH 
BD Pharm Lyse buffer BD Biosciences 
40μm cell strainer Greiner 









RTCA software ACEA Biosciences 
Tecan i-control TECAN Group Ltd. 
BD FACS Diva BD Biosciences 
Flow Jo X TreeStar 

















6.2.1. Generation and analysis of ATPP and FRET conjugates 
 
6.2.1.1. Antibodies used for ATPP generation 
Anti-CD22 and anti-CD79b antibodies were kindly provided by Eike Hoffmann (Large 
Molecule Research, Roche Diagnostics GmbH, Penzberg). Anti-CD138 antibody 
was received from Martin Kuen (Discovery Oncology, Roche Diagnostics GmbH, 
Penzberg). The anti-CDCP1 (CD318, RG-7287) antibody was generated as 
described190. Anti-CD22, anti-CD79b and anti-CDCP1 antibodies carried the P329G 
LALA mutation for abolished binding to Fc-gamma receptors (FcRγ). Antibodies 
were stored in 0.1M potassium phosphate buffer containing 150 mM NaCl, pH 7.5 at 
-20°C for short or -80°C for long term, respectively. 
 
 
Table 6.1 – Peptides used for ATPP generation 
Abbreviation Peptide sequence Species Gene HLA class I 
binding* 
pEBV_CLG CLGGLLTMV EBV LMP-2 HLA-A02:01 
pEBV_GLC GLCTLVAML EBV BMLF-1 HLA-A02:01 





* only HLA genes relevant to performed experiments are considered.  
 
 
6.2.1.2. Generation of peptides and ATPP conjugates 
Utilized peptides are summarized in Table 6.1 and were synthesized using standard 
Fluorenylmethyloxycarbonyl (Fmoc)-chemistry.  Both peptides and ATPPs were 
generated in the laboratory of Lars Hillringhaus (Peptide Chemistry, Roche 
Diagnostics GmbH, Penzberg). All generated ATPP conjugates are summarized in 
Supplemental Figure 9.1. Antibodies were mixed with 8 equivalents of N-
Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP, Pierce) for two hours of reaction 
time. Hereafter, 0.1 M potassium phosphate buffer containing 150 mM NaCl  and 10 
REFERENCES  36 
 
 
mM EDTA (pH 7.0) was used for dialysis of the derivatized antibody. Next, 6 
equivalents of the respective peptide were added and incubated overnight. The final 
product was dialyzed against storage buffer (20mM Histidine, 150mM NaCl) and 
stored at -20°C.  
ATPP conjugates containing a non-cleavable thioether linker were generated 
according to the mentioned protocol using succinimidyl iodoacetate (SIA, Pierce) 
instead of SPDP. 
 
6.2.1.3. Mass spectrometric analysis of ATPP peptide labeling rates 
ATPP conjugates were analyzed by mass spectrometry in the laboratory of Gloria 
Tabares (Protein Chemistry, Roche Diagnostics GmbH, Penzberg), in order to 
determine the average peptide labeling rates. ATPPs and unlabeled reference 
antibodies were deglycosylated using N-glycosidase F and analyzed by means of 
liquid chromatography electrospray ionisation mass spectrometry  (LC-ESI-MS) 
using a high pressure liquid chromatography (HPLC) System (Waters) in 
combination with a reverse-phase column containing a water-acetonitrile gradient 
and subsequent electrospray ionisation time of flight mass spectrometry (ESI-TOF-
MS) measurement and detection. Data analysis was performed using the MassLynx 
Software (Waters).  
 
6.2.1.4. Synthesis of the anti-CDCP1-FRET construct 
Generation of the FRET construct was adapted from Yang et al.191 and performed in 
the laboratory of Lars Hillringhaus (Peptide Chemistry, Roche Diagnostics GmbH, 
Penzberg). Fmoc-chemistry was applied to generate the following linker peptide: 
Acetyl-Cys-Lys-Ala-Glu-ßAla-Glu-ßAla-Glu-Aha. After peptide cleavage from the 
TentaGel R RAM resin, the peptide was purified by preparative HPLC. Next, 
cysteamine dithiopyridyl (1 equivalent) and trimethylamine (4 equivalents) were 
dissolved in dimethylformamide (DMF) and reacted with a solution of sulforhodamine 
B acid chloride (1 equivalent). 2 equivalents of the resulting rhodamine dithiopyridine 
were incubated with the linker peptide (1 equivalent) in phosphate buffer at pH7.5. 
After 90 minutes, 4,4-difluoro-5,7-dimethyl-4-bora-3α,4α-diaza-s-indacene-3-
propionic acid (BODIPY) FL N-hydroxy-succinimide (NHS) ester (2 equivalents) was 
added and incubated for 90 minutes. The resulting FRET peptide was purified by 
preparative HPLC. 
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The αCPDP1 antibody was incubated with 5 equivalents of cyclooctyne NHS ester 
(SX-A1028, Synaffix) in phosphate buffer at pH 8.3 and subsequently purified by gel 
filtration. The resulting αCPDP1-cycloctyne conjugate was incubated with 30 
equivalents of FRET peptide in phosphate buffer at pH 7.0 for 3 hours and the final 
αCPDP1-FRET conjugate was purified by gel filtration and stored in 20mM histidine, 
150mM NaCl at -20°C. 
 
 
6.2.2. Cell culture 
 
6.2.2.1. Cell lines and culture conditions 
Utilized cancer cell lines were originally purchased from the American Type Culture 
Collection (ATCC) and were provided by Roche cell bank, where they were verified 
as pathogen-free and identity was confirmed by means of single nucleotide 
polymorphism (SNP)-PCR or short tandem repeat (STR) analysis. Cell lines were 
grown in a humidified incubator at 37°C supplied with 5% CO2 in dedicated media as 
specified in Table 6.2. U266B1 cells were grown in low-adherence flasks. Before in 
vivo inoculation the absence of murine pathogens was additionally confirmed by 
PCR analysis.  
 
 
Table 6.2 – Utilized cancer cell lines 
Cell line Cancer type Cell culture medium 
MDA-MB231 breast RPMI1640, 10%FBS, 2mM L-
Glutamine 
HCT-116 colon McCoy´s 5A, 10%FBS, 2mM L-
Glutamine 
A375 skin (melanoma) DMEM, 10% FBS, 2mM L-Glutamine 
PC-3 prostate RPMI1640, 10% FBS, 2mM, L-




RPMI1640, 10% FBS, 2mM, L-
Glutamine, 1mM Sodium Pyruvate, 
10mM HEPES 
U266B1 blood (multiple 
myeloma) 
RPMI1640, 15% FBS, 2mM, L-
Glutamine, 1mM Sodium Pyruvate, 
10mM HEPES 





6.2.2.2. Passaging and counting of cells 
Cancer cell lines were grown to 70-100% confluency, subsequently passaged for a 
maximum of 5 times and freshly thawed thereafter. Cells were detached by means of 
accutase, resuspended in FBS-containing medium and collected by means of 
centrifugation (300g, 3min). Cell numbers were determined by means of the Vi-Cell 
XR Cell Viability Analyzer. 
 
6.2.2.3. Freezing and thawing of cells 
Cells were frozen in FBS containing 10% DMSO. Cryo tubes were placed in CoolCell 
(Biocision) freezing containers and incubated at -80°C. After 2 days tubes were 
transferred to liquid nitrogen and stored until required.  
Thawing of cells was performed by placing cryo tubes in a 37°C water bath for 
approximately 30 seconds. Next, cell suspension was mixed with equivalent volume 
of pre-warmed media and subsequently transferred to falcon tubes containing the 
same medium. Cells were pelleted by centrifugation (300g, 3min) to remove DMSO. 




6.2.3. Isolation of PBMCs from human blood and in vitro expansion of   
peptide-specific T cells 
 
6.2.3.1. Isolation of PBMCs from human blood 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient 
centrifugation from EDTA-blood of healthy donors (employees of Roche Diagnostics 
GmbH, Medical Services Department, Penzberg). For this purpose, equal volumes of 
blood and PBS were mixed and 35mL were transferred to 50mL Leucosep tubes 
(Greiner). After 20min centrifugation (800g, w/o break) at room temperature (RT), the 
PBMC containing interphase was transferred to 50mL falcon tubes and mixed 1:1 
with PBS. To remove platelets, PBMCs were washed 3 times with PBS (250g, 
10min). PBMCs were frozen as described in section 6.2.2.3. 
 




6.2.3.2. CD8+ T cell isolation from human blood 
The RosetteSep™ Human CD8+ T Cell Enrichment Cocktail (StemCell) was used 
according to the manufacturer´s instructions, in order to isolate CD8+ T cells from 
human blood.  This cocktail isolates CD8+ T cells by negative selection using 
bispecific antibodies, which pellet the unwanted cells along with the erythrocytes 
during Ficoll gradient centrifugation. Hence, the interphase is supposed to only 
contain CD8+ T cells. The enrichment quality was subsequently investigated using 
flow cytometry. 
 
6.2.3.3. Expansion of peptide-specific T cells from human PBMCs 
2x105 freshly isolated PBMCs were cultured per u-bottomed 96-well in 200μL RPMI+ 
medium (RPMI1640, 8% heat-inactivated human AB serum, 1mM Sodium Pyruvate, 
1mM non-essential amino acids, 2mM L-Glutamine, 50μM β-mercaptoethanol and 
PenStrep) containing 1μM of the respective peptide (Table 6.1). After 3 days and 
again on day 10, 150μL of medium were exchanged and fresh peptide and 20ng/mL 
Interleukin 15 (IL-15) and 500ng/mL soluble, Fc-fused IL15-Receptor alpha 
(sIL15Ra-Fc, R&D Systems) were added. Until day 20, similar medium exchange 
without peptide addition was performed if required. On day 20, 5-10x107 T cells were 
transferred to G-Rex10 cell culture containers in 10mL old medium and restimulated 
with peptide-pulsed, irradiated, autologous PBMCs (1:1). PBMCs were thawed as 
described in section 6.2.2.3 and incubated with 0.1mg/mL DNase I and 5μM peptide 
for 1 hour at 37°C, 5%CO2. After irradiation with 40Gy, PBMCs were washed twice in 
RPMI1640/10%FBS (300g, 10min) and subsequently added to T cells. G-Rex10 
containers were filled up to 40mL with RPMI+ and 20ng/mL IL-15 and 500ng/mL 
sIL15Ra-Fc were added. Cells were restimulated every two weeks with irradiated 
(80Gy), peptide-pulsed lymphoblastoid cells (LCLs) and expanded every 4-5 days 
with fresh medium supplemented with IL-15 and sIL15Ra-Fc as indicated above. 
Peptide-specific expansion of T cells was monitored on a regular basis by flow 
cytometric analysis using MHC-peptide pentamers. Cultures used for functional 








6.2.3.4. ATPP-mediated expansion of peptide-specific T cells  
2x105 freshly isolated PBMCs were cultured per u-bottomed 96-well in 200μL RPMI+ 
medium (RPMI1640, 8% heat-inactivated human AB serum, 1mM Sodium Pyruvate, 
1mM non-essential amino acids, 2mM L-Glutamine, 50μM β-mercaptoethanol and 
PenStrep) containing 13, 1.3 or 0.13nM of the EBV_CLG peptide or the respective 
CD22- or CD79b-targeting ATPP. After 3 days and again on day 10, 150μL of 
medium were exchanged and fresh peptide or ATPPs and 20ng/mL Interleukin 15 
(IL-15) and 500ng/mL soluble, Fc-fused IL15-Receptor alpha (sIL15Ra-Fc, R&D 
Systems) were added. Cells were expanded every 4-5 days with fresh medium 
supplemented with IL-15 and sIL15Ra-Fc as indicated above. Peptide-specific 
expansion of T cells was monitored by flow cytometric analysis using MHC-peptide 
pentamers on day 13, 20 and 26. 
 
 
6.2.4. Flow cytometric analyses 
 
6.2.4.1. Target, HLA expression and ATPP binding on tumor cell lines 
Cancer cells were detached by means of accutase and washed in FBS-containing 
medium (300g, 3min).  2x105 cells were transferred per v-bottomed 96-well, washed 
and stained in 100μL of FACS buffer (PBS, 3% FBS, 2mM EDTA) containing 
respective primary antibodies, isotype control antibodies or ATPPs for 20min at 4°C.  
Cells were washed three times in FACS buffer and – in case required – incubated 
with secondary antibodies in FACS buffer for 20min at 4°C. 1μg/mL DAPI was added 
either to primary or secondary antibodies, in order to stain dead cells. While primary, 
secondary and isotype control antibodies were used according to the manufacturers 
instructions, ATPPs or respective uncoupled antibodies were used at 10μg/mL. 
Following three additional washing steps in FACS buffer, Flow cytometry was 
performed using the BD Biosciences Canto II and data was analyzed by means of 
the FlowJo (Treestar) software. 
 
6.2.4.2. ATPP internalization on tumor cells 
Cancer cells were harvested by means of accutase and washed in FBS-containing 
medium (300g, 3min).  2x105 cells were transferred per v-bottomed 96-well and 
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stained in 100μL of cell culture medium containing 10μg/mL of ATPPs, the 
respective uncoupled antibody or the corresponding human IgG isotype control 
antibody (Sigma) for 30min at 4°C. Cells were washed three times and subsequently 
incubated in cell culture medium at 4°C and 37°C. After t=0, 0.5, 1, 2, 4 and 23hours, 
cells were stained with secondary antibody for 30min on ice (polyclonal goat anti-
human IgG-Alexa488, Life technologies) to detect non-internalized ATPPs at the cell 
surface. 1μg/mL DAPI was added to stain dead cells. Cells were washed three times 
in FACS buffer (PBS, 3% FBS, 2mM EDTA), samples were run at the BD FACS 
Canto II and data was analyzed by means of the FlowJo (TreeStar) software. 
Percent internalization for each time-point was calculated as follows: (MFI at 37°C / 
MFI at 4°C) x 100.  
 
6.2.4.3. Analysis of peptide-specific T cells 
5-10x105 PBMCs or T cells were transferred per v-bottomed 96-well, washed (300g, 
2min) and stained in 100μL FACS buffer (PBS, 3% FBS, 2mM EDTA) containing 
respective peptide-MHC pentamers (1:10, ProImmune) for 1 hour at 4°C. Having 
washed three times in FASC buffer, cells were incubated in 50μL FACS buffer 
containing 5μL human TruStain fcX™ (BioLegend) for 15min at 4°C, in order to block 
human Fc receptors. For analysis of isolated tumor xenografts, cells were 
additionally incubated with TruStain fcX™ (anti-mouse CD16/32 Ab, BioLegend). 
Next, 50μL FACS buffer containing primary antibodies and 1μg/mL DAPI were 
added and incubated for 20min at 4°C. Finally, cells were washed three times in 
FACS buffer and subjected to flow cytometric analysis at the BD FACS Canto II. 
Data were analyzed by means of the FlowJo (TreeStar) software.  
 
 
6.2.5. T cell activation and cytotoxicity assays 
 
6.2.5.1. Interferon-γ ELISPOT 
The Human IFN-γ ELISpot PRO kit (Mabtech, #3420-2APT) was used according to 
the manufacturer´s instructions, in order to investigate ATPP-mediated T cell 
activation. The kit uses alkaline phosphatase (ALP)-conjugated antibodies for one-
step visualization of released Interferon-γ (IFNγ) by means of BCIP/NBT-plus 
substrate. 
REFERENCES  42 
 
 
Pre-coated 96-well plates were washed 4 times with PBS, tumor cells were 
harvested by means of accutase and 1x104 tumor cells were plated per well in 200μL 
of respective cell culture media. Tumor cells were treated with ATPPs, peptides or 
control antibodies and placed in the incubator for 20-24 hours, if not stated 
otherwise. Plates were wrapped in aluminum foil during the incubation period. Next, 
adherent tumor cells were washed once with 150μL AIM-V medium and 200 in vitro 
expanded, peptide-specific CD8+ T cells were added in 200μL AIM-V medium. After 
24 hours incubation at 37°C, 5%CO2, ELISPOT plates were developed and – after 
drying – analyzed by means of the ImmunoSpot S5 Analyzer (CTL) using the 
ImmunoSpot 5.0 software. 
 
6.2.5.2. Interferon-γ ELISA 
The Human IFN-gamma DuoSet ELISA kit (R&D Systems, #DY285) was used 
according to the manufacturer´s instructions, in order to investigate ATPP-mediated 
T cell activation. The kit uses the sandwich ELISA setup and streptavidin-conjugated 
horseradish peroxidase (HRP) for visualization of released interferon-γ (IFNγ) in the 
supernatant.  
Tumor cells were harvested by means of accutase and 1.5x104 tumor cells were 
plated per well of a flat-bottomed 96-well plate in 200μL of respective cell culture 
media. Tumor cells were treated with ATPPs, peptides or control antibodies and 
placed in the incubator for 20-24 hours. Next, adherent tumor cells were washed 
once with 150μL AIM-V medium and 4.5x104 in vitro expanded, peptide-specific 
CD8+ T cells or 3x105 CD8+ T cell-enriched PBMCs were added in 200μL AIM-V 
medium. U266B1 cells were transferred to v-bottomed 96-well plates and centrifuged 
(2min, 300g) for washing. For MHC blocking experiments, αHLA-ABC antibody 
(clone W6/32, BioLegend) was added to tumor cells 10min before T cell addition. 
After 24 hours incubation at 37°C, 5%CO2, samples were transferred to v-bottomed 
96-well plates, supernatants were collected after centrifugation (2min, 300g) and 
directly used or frozen at -20°C. 
Flat-bottomed 96-well MaxiSorp® plates (Nunc) were coated with 50μL of the diluted 
IFNγ capturing antibody (1:120 in PBS) over night at RT. After blocking for at least 2 
hours in blocking buffer (PBS, 1%BSA), 50μL of assay supernatants were 
transferred per well and incubated for 2 hours at RT. After washing, 50μL of the 
diluted detection antibody (1:60 in PBS, 0.1% BSA, 0.05% Tween®20, 2%NGS) 
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were added and incubated for 2 hours at RT. Having washed again, 50μL of diluted 
Streptavidin-HRP (1:40 in PBS, 0.1% BSA, 0.05% Tween®20) were added and 
incubated for 20min at RT. After washing, ELISA plates were developed using 50μL 
of the BM Blue POD Substrate solution (Roche Diagnostics GmbH). Development 
was stopped by adding 50μL of 1M H2SO4. Washing between different steps was 
performed by means of the MicroTek ELISA plate washer applying four wash steps 
with 200μL of washing buffer (PBS, 0.05% Tween®20 was used for washing of 
plates. Tween 20 (Roche Diagnostics GmbH), bovine serum albumin (BSA, Sigma 
Aldrich) and normal goat serum (NGS, R&D Systems) were used for buffers. ELISA 
plates were analyzed by measuring absorbance at 450nm and 620nm (reference 
wavelength) by means of the Infinite 200Pro plate reader (TECAN Group Ltd.) using 
the Tecan i-control software. Reference values were subtracted from the absorbance 
and final IFNγ concentrations were calculated based on a calibration curve. 
 
6.2.5.3. LDH release assay 
Tumor cells were harvested by means of accutase and 1.5x104 tumor cells were 
plated per well of a flat-bottomed 96-well plate in 200μL of respective cell culture 
media. Tumor cells were treated with ATPPs, peptides or control antibodies and 
placed in the incubator for 20-24 hours. Next, adherent tumor cells were washed 
once with 150μL AIM-V medium and in vitro expanded, peptide-specific CD8+ T cells 
or CD8+ T cell-enriched PBMCs were added at different effector-to-target ratios in 
200μL AIM-V medium. After 24 hours incubation at 37°C, 5%CO2, samples were 
transferred to v-bottomed 96-well plates, supernatants were collected after 
centrifugation (2min, 300g) and directly used or frozen at -20°C. 
100μL of assay supernatant were transferred per well of flat-bottomed 96-well plates. 
The Cytotoxicity Detection Kit (Roche Diagnostics GmbH) was used according to the 
manufacturer´s instructions in order to measure LDH activity. 100μL of freshly 
prepared reaction mixture were added per well and after 5-15min absorbance was 
detected at 492nm (reference: 620nm) using the Infinite 200Pro plate reader 
(TECAN Group Ltd.) in combination with the Tecan i-control software. Maximum 
LDH release was determined by lysing target cells with 1% Triton X-100 (Sigma-
Aldrich). Percentage of lysis was calculated as [(LDH release during treatment – 
LDH release of target cells)/(maximum LDH release – LDH release of target cells) x 
100]. 




6.2.5.4. Real-time cytotoxicity detection by xCELLigence 
For real-time analysis of target cell killing the xCELLigence analyzer (ACEA 
Biosciences) was used, where the impedance is regularly measured at the bottom of 
a well and serves as a correlate for cell attachment and viability.  
50μL of cell culture medium were added per well of a 96-well E-plate (ACEA 
Biosciences) and background measurement was performed at the xCELLigence 
RTCA instrument. Tumor cells were harvested by means of accutase and 1.5x104 
tumor cells were added in 150μL of cell culture media. Tumor cells were treated with 
ATPPs, peptides or control antibodies and placed in the incubator for approximately 
24 hours. When cell indices >1.0 were reached, adherent tumor cells were washed 
once with 150μL AIM-V medium and 4.5x104 in vitro expanded, peptide-specific 
CD8+ T cells were added in 200μL AIM-V medium. Cell indices were monitored and 
normalized to the time point of T cell addition. Target cell killing in % was calculated 
as [(cell index of target cells – cell index treatment)/(cell index of target cells] x 100. 
 
 
6.2.6. Confocal microscopy 
 
6.2.6.1. Time-lapse imaging of ATPP-mediated tumor cell killing by T cells 
Time-lapse imaging was established and performed in the laboratory of Olaf Mundigl 
(Large Molecule Research, Roche Diagnostics GmbH, Penzberg). Ibidi μ-dish 
chambers (Culture-Insert 2 Well in µ-Dish 35 mm, Ibidi, # 81176) were coated with 
Collagen type I (Sigma) at 10µg/cm2 for 3-4 hours at RT and washed twice with PBS 
afterwards. 3x103 HCT-116 tumor cells were plated per well in 100µL cell culture 
medium. After 2 days, medium was exchanged and tumor cells were treated with 
0.132nM αCDCP1-CLG or control αCD22-CLG ATPP over night. After 20 hours 
tumor cells were stained for 15min with 2μM 5-Chlormethylfluorescein-diacetat 
(CMFDA, Life technologies) in cell culture medium at 37°C, 5%CO2 and in vitro 
expanded, peptide-specific CD8+ T cells were labeled for 3min with 2μM PKH26 
(Sigma Aldrich) in supplied buffer. Cells were washed twice with PBS and T cells 
were added in phenol red-free RPMI1640 supplemented with 2%FBS at an effector-
target ratio of 2:1. Time-lapse fluorescence imaging was performed in a 37°C, 
5%CO2, 95% humidity chamber on a Leica SP8 microscope using hybrid detectors 
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(HyD) and a 63x/1.20 water immersion lens with sequential acquisition for each 
channel. CMFDA signals were acquired using white light laser excitation at 488nm 
and emission at 492-553nm while PKH26 was excited at 561nm and detected at 
567-670nm. 
 
6.2.6.2. FRET Imaging 
FRET imaging was established and performed in the laboratory of Olaf Mundigl 
(Large Molecule Research, Roche Diagnostics GmbH, Penzberg). 1x105 MDA-
MB231 cells were grown on cover slips for 24 hours and pulsed with 10μg/mL of 
αCDCP1-FRET conjugate for 30min on ice. Cells were washed twice with PBS, 
incubated in cell culture medium for t=0, 2 or 18 hours at 37°C, 5%CO2 and 
subsequently fixed with 4% PFA. To investigate donor (BODIPY) and antibody co-
localization Alexa Fluor 647 conjugated αIgG (H+L) antibody (Life technologies) was 
used. Confocal microscopy was performed on a Leica SP8 microscope using hybrid 
detectors (HyD) and a 100x/1.46 N.A. oil immersion lens with sequential acquisition 
for each channel. BODIPY signals were acquired using white light laser excitation at 
488nm and emission at 492-553nm, while Rhodamine was detected at 567-670nm. 
Alexa Fluor 647 was excited at 647nm and detected at 653-700nm. 
 
 
6.2.7. In vivo experiments and harvest of sample material 
 
6.2.7.1. Animal facility 
Animals were housed under specified pathogen free (SPF) conditions in the animal 
facility of Roche Diagnostics GmbH in Penzberg in compliance with national and 
international regulations. The facility is accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care (AAALAC), hence demonstrating its 
commitment to responsible and humane animal care. Mice were tested for defined 
pathogens on a regular basis according to the guidelines of the Federation of 
Laboratory Animal Science Associations (FELASA). Mice were kept in a 12-hour 
dark/light-rhythm and fed with autoclaved standard diet. Hemp pads were used for 
environmental enrichment. Cages, food pellets, water bottles and bedding were 
exchanged by animal caretakers on a weekly basis and animals were monitored 
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daily for general health conditions. All experiments were approved by the 
Government of Upper Bavaria. 
 
6.2.7.2. Animals used for experiments 
Female CIEA NOG mice® were purchased from Taconic Biosciences and used for 
experiments at the age of 5-7 weeks, but not before an adaption period of at least 
one week after arrival.  
The CIEA NOG mouse® was developed by Mamoru Ito at the Central Institute for 
Experimental Animals (CIEA, Japan). Besides hampered innate immune 
components derived from the NOD inbred strain, such as macrophage and 
complement dysfunctions, NOG mice exhibit two major mutations leading to its 
immunodeficiency and thus enabling engraftment of human immune cells. These 
include the so-called severe combined immunodeficiency (SCID) mutation, which is 
an autosomal recessive mutation of the Prkdc gene (Prkdcscid; protein kinase, DNA 
activated, catalytic polypeptide), an enzyme involved in DNA repair. As a result, VDJ 
recombination is impaired leading to the inability to generate mature B and T 
lymphocytes.  In addition, the animals are homozygous for a loss-of-function 
mutation in the interleukin-2 receptor (IL-2R) gene, also known as the common 
cytokine receptor gamma chain, which is encoded on the X-chromosome. As the 
common gamma chain (γc) is an important component of the high-affinity receptors 
for various cytokines including IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, the γcnull 
mutation – besides impairing T and B cell development – results in lack of NK cells 
and dendritic cell dysfunctions. 
 
6.2.7.3. Tumor inoculation, measurements and calculation of tumor volumes 
For in vivo experiments tumor cells were expanded in cell culture medium without 
antibiotics and tested for the absence of murine pathogens. Cells were detached by 
means of accutase, washed once in FBS containing medium, once in PBS and 
finally resuspended at 5x107 cells/mL in PBS. 
The right flank of mice was carefully shaved and mice were anesthetized by means 
of isoflurane. 5x106 tumor cells were injected subcutaneously in 100μL PBS per 
mouse. 
Tumor growth as well as body weight were measured 2-3 times per week by means 
of a caliper or a laboratory scale, respectively. Ellipsoid tumor volumes were 
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calculated as follows: Tumor volume [mm3] = length of tumor [mm] * (width of tumor 
[mm])2 / 2. 
 
6.2.7.4. Adoptive transfer of human T cells 
Human blood donors were tested for absence of HIV and Hepatitis B/C infections. In 
vitro expanded, human, EBV_CLG peptide-specific CD8+ T cells were collected by 
centrifugation for 5min at 300g. T cells were washed once in PBS and subsequently 
resuspended in PBS containing 15μg/mL IL-15 and 70μg/mL sIL15Ra-Fc (R&D 
Systems).  Depending on the experiment, 5 or 10x106 T cells were injected 
intravenously into the tail vein per mouse in 100μL PBS containing 1.5μg IL-15 and 
7μg sIL15Ra-Fc. 
 
6.2.7.5. Necropsy and harvest of sample material 
Mice were sacrificed by cervical dislocation. Tumors were excised with a scalpel and 
tumor weight was determined by means of a laboratory scale. Harvested spleens 
and tumors were collected in RPMI1640 medium and stored on ice until further 
processing. 
 
6.2.7.6. Treatment with ATPPs and antibodies 
After randomization and assignment to treatment and control groups animals were 
injected intraperitonally with ATPPs or unconjugated control antibodies. Depending 
on the experiment, mice were injected (1q/3d) with 10mg/kg per week of the IgG4-
based constructs or with 20mg/kg per week of the conjugates with IgG1 backbone 
carrying the P329G LALA mutation for abolished FcRγ binding. ATPPs or control 
antibodies were diluted in PBS and administered in a final volume of 100μL. Anti-
human PD1 monoclonal antibody (αPD1 Ab) was kindly provided by Stefan Seeber 
(Large Molecule Research, Roche Diagnostics GmbH, Penzberg). αPD1 Ab was 
also administered in 100μL after dilution in PBS (5mg/kg/week, 1q/7d). Tested 
compounds exhibited endotoxin levels <0.16 EU/mL. 
 
6.2.7.7. Processing of tumors for flow cytometry 
Harvested tumors were transferred to 6-well plates and sliced into small pieces by 
means of a scalpel. Tumor pieces were transferred into 50mL falcon tubes and 
digested in 5mL RMPI1640 medium containing 1mg/mL Dispase II (Roche 
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Diagnostics GmbH), 1mg/mL Collagenase IV (Sigma Aldrich) and 0.1mg/mL DNase I 
(Roche Diagnostics GmbH). After digestion for 15min at 37°C under slow rotation 
(12-15rpm), the digest was transferred through a 70μm cell strainer by gently 
pressing the tumor through the sieve with the plunger of a syringe. The mesh was 
washed with 20mL FACS buffer (PBS, 3% FBS, 2mM EDTA) and the tumor cell 
suspension was collected by centrifugation (300g, 5min, RT). All following steps 
were performed at 4°C or on ice. The cell suspension was strained through a 40μm 
cell strainer, collected by centrifugation and finally transferred into v-bottomed 96-
well plates for subsequent staining and analysis by flow cytometry. 
 
6.2.7.8. Processing of spleens for flow cytometry 
Harvested spleens were cleaned from contaminating tissue and transferred through 
a 70μm cell strainer by gently pressing the tissue through the sieve with the plunger 
of a syringe. The mesh was washed with 30mL RPMI1640 medium and the tumor 
cell suspension was collected by centrifugation (300g, 5min, RT) in 15mL falcon 
tubes. For lysis of red blood cells 5mL of BD Pharm lyse buffer (BD Biosciences) 
were added per tube and cells were resuspended with a 1mL pipet. After incubation 
for 5min at RT under slow rotation, lysis was stopped by adding 30mL of cold FACS 
buffer (PBS, 3% FBS, 2mM EDTA). All following steps were performed at 4°C or on 
ice. The cell suspension was strained through a 40μm cell strainer, collected by 
centrifugation and finally transferred into v-bottomed 96-well plates for subsequent 
staining and analysis by flow cytometry. 
 
 
6.2.8. Statistics and data analysis 
 
6.2.8.1. Analysis of in vitro data 
In vitro data was analyzed and graphs were generated by means of the Microsoft 
Excel software. Experiments were performed at least twice with a minimum of 3 
replicates. 
 
6.2.8.2. Analysis of in vivo data 
In vivo data was analyzed and graphs were generated by means of the GraphPad 
Prism software. Statistical analysis of experimental data was performed using one-
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way ANOVA followed by Turkey´s multiple comparison test comparing the mean of 
each data set with every other mean with a 95% confidence interval. Results were 
considered statistically significant if p <0.05. Tumor growth inhibition in % was 
calculated as [[(Vcend-Vcstart) – (Vtend-Vtstart)] / (Vcend-Vcstart)]*100, where Vc, Vt are the 
mean tumor volumes of control and treated groups at the start (staging of tumors) or 
end of the study.  




7.1. Generation of ATPP immunoconjugates 
We generated a panel of antibody immunoconjugates called antibody-targeted 
pathogen-derived peptides (ATPPs) by conjugating virus-derived, cysteine-
containing peptides to free amino groups of lysine residues on tumor antigen-specific 
antibodies via N-Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) linkers (Figure 
7.1). Peptides were covalently bound to SPDP linkers via their cysteines, generating 
a disulfide bond. Average peptide labeling rates were determined by mass 
spectrometry and can be found in Supplemental Figure 9.1d. Immunodominant 9-
mers from Epstein-Barr virus (EBV) or Influenza A (INF) were selected for 
conjugation, which can readily bind to HLA-A02:01 or -A01:01 molecules, 
respectively. The peptides and their corresponding sequences are summarized in 
Table 6.1. 
Choosing the integral membrane protein CUB-domain-containing-protein-1 (CDCP1) 
as primary proof of concept target allowed testing of the ATPP approach in multiple 
cancer cell lines, as CDCP1 is highly expressed in various cancer types. Moreover, 
the target efficiently internalizes upon binding of the receptor-specific antibody190. 
 
Figure 7.1 Generation of ATPP immunoconjugates.  
ATPP conjugates were generated by covalently binding N-Succinimidyl 3-(2-pyridyldithio)-propionate 
(SPDP) linkers to the free amino group of lysine residues on utilized antibodies. Subsequently, 
cysteine-containing peptides (red) were linked via their thiols, generating a disulfide bond between the 
peptide and the linker. In the illustration, one peptide was randomly coupled to the antibody, while in 
theory any lysine residue offers a possibility for linker and subsequent peptide attachment. CH: 
constant and VH: variable domains of antibody heavy chains (dark blue). CL: constant and VL: variable 
domains of antibody light chains (light blue). C on peptide indicates cysteine. ATPP conjugates were 
generated in the laboratory of Lars Hillringhaus (Peptide Chemistry, Roche Diagnostics GmbH, 
Penzberg). 
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Importantly, utilized antibodies had a human IgG1 backbone and carried the P329G 
LALA mutation for abolished binding to Fc-gamma receptors (FcγR)195. Hence, the 
antibodies did not bind to FcγRI, FcγRII and FcγRIII, whereas FcRn (neonatal Fc-
receptor) binding was unchanged, leading to IgG-like half-life and pharmacokinetics. 
As the mutations also prevent interactions with components of the complement 
system, antibodies do neither exhibit antibody-dependent cellular cytotoxicity 
(ADCC) nor complement-dependent cytotoxicity (CDC).  
 
7.2. Phenotypic characterization and selection of target cells 
In order to investigate the functionality of generated ATPP conjugates, we had to 
choose cancer cell lines expressing both the target as well as the respective HLA 
molecules that allow peptide binding. Along this line, CDCP1-positive (CDCP1+) cell 
lines were pre-selected by mRNA expression and further analyzed by flow cytometry 
for CDCP1 and HLA-A1 and -A2 expression (Figure 7.2). As there is no 
commercially available HLA-A1 targeting antibody, we had to apply combined 
analysis for HLA-A1/11/26 and HLA-A1/36 (Figure 7.2d, g). Based on these data we 
selected 5 cell lines, which exhibited differing expression levels of CDCP1 and HLA 
molecules. These included a breast cancer (MDA-MB231), a colorectal cancer 
(HCT-116), a prostate cancer (PC-3), a pancreatic cancer (BxPC-3), as well as a 
melanoma (A-375) cell line. The corresponding CDCP1 and HLA expressions, 
including relevant HLA genotypes are summarized in Table 7.1. 
 
 
Table 7.1 – CDCP1 and HLA expression on utilized cancer cell lines 
Cancer  
cell lines 
CDCP1 HLA-A2  HLA-A1/A11/A26 HLA-A1/A36 
MDA-MB-231 36,366 147,187 (A2*01, A2*17) - - 
HCT-116 47,678 7,990  (A2*01) 24,679 (A1*01) 1,747 (A1*01) 
A-375 1,736 8,629 (A2*01) 21,758 (A1*01) 710 (A1*01) 
PC-3 43,488 - 24,452 (A1*01) 1,336 (A1*01) 
BxPC-3 16,632 - 35,430 (A1*01) 2,069 (A1*01) 
Values represent mean fluorescence intensity (flow cytometry). Brackets indicate relevant HLA 
genotypes, as determined by PCR-based genotyping (ProImmune Ltd.). 
 
 



















































Figure 7.2 Characterization of tumor cell lines according to HLA 
and target expression. 
(a) Representative gating strategy and (b) flow cytometric analysis 
of CDCP1, (c) HLA-A2 and (d) HLA-A1 expression, shown for HCT-
116 cells. (e) mRNA as well as flow cytometry-derived CDCP1, (f) 
HLA-A2 and (g) HLA-A1 protein expression. MFI: mean 
fluorescence intensity. mRNA data were provided by Fabian Birzele 
(Roche Pharmaceutical Sciences) and derived from the Roche 
CELLO database. FACS data were partially generated in 
collaboration with Dominique Ostler (Discovery Oncology, Roche 
Diagnostics GmbH, Penzberg). 
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7.3. Generation of peptide-specific CD8+ T lymphocytes as effector cells 
Having selected the appropriate target cells, we next sought to expand peptide-
specific CD8+ T lymphocytes from human blood, which could be used as effector 
cells in the following experiments. For this purpose we screened a variety of human 
donors for HLA-A1/-A2 positivity and the abundance of peptide-specific CD8+ T cells 
(Figure 7.3). In this respect, peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll gradient centrifugation and subjected to flow cytometric analysis 
using peptide-MHC pentamers. A representative analysis for the abundance of 
EBV_CLG peptide-specific T cells is depicted in Figure 7.3a. After establishing a 
method for in vitro generation of peptide-specific CD8+ T cell cultures by bi-weekly 
stimulation with peptide-loaded, autologous PBMCs or lymphoblastoid cells (LCLs), 
expansion was monitored by flow cytometric analysis using peptide-MHC pentamers 
(Figure 7.4). Cultured T cells were used as effector cells, when they exhibited 80-
100% peptide-specificity. Importantly, the expansion protocol generated CD8+ 
effector memory T cells as revealed by  CD45RO+ CCR7-  expression  (Figure 7.5b), 
 
 
Figure 7.3 Characterization of blood donors according to HLA status and abundance of peptide-
specific T cells. 
PBMCs from healthy blood donors were subjected to flow cytometric analysis. (a) Representative 
gating strategy to screen for peptide-specific CD8+ T cells. Here, the abundance of EBV_CLG 
peptide-specific CD8+ T cells was analyzed after gating on CD3+CD4-CD8+ cells. (b) Flow cytometric 
analysis of HLA-A2 expression on donor-derived PBMCs. A comparison between an HLA-A2- (grey) 
and an HLA-A2+ donor (black) is shown.  
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while 75% of peptide-specific CD8+ T cells in peripheral blood of donors exhibited a 
CD45RO+ CCR7+ central memory phenotype (Figure 7.5a).  
In order to prove the functionality and specificity of expanded T cells, we investigated 
their capacity to secrete interferon-gamma (IFNγ) in response to antigenic 
stimulation by tumor cells loaded with the respective HLA-A02:01-binding EBV_CLG 
peptide. Expectedly, T cells only secreted IFNγ when encountering peptide-pulsed 
MDA-MB231 cells, but not when applying untreated tumor cells, as determined by 
IFNγ-ELISPOT (Figure 7.6a). When comparing all screened tumor cell lines, HLA-
A2+ MDA-MB231, HCT-116 and A-375 cells mediated strong T cell activation after 
peptide-loading  (Figure 7.6b), again highlighting their usability to investigate ATPP 
functionality. As expected, HLA-A2- cell lines did not trigger T cell stimulation, when 




7.4. ATPPs bind to the target and become internalized 
As depicted in Figure 5.1, the ATPP concept requires binding of antibodies to the 
target on the cell surface and subsequent internalization of ATPP-receptor 
complexes into the endosomal compartment, where peptide release is supposed to 
occur. Since SPDP-linked peptides were randomly conjugated to lysines on the 
antibody  and  hence could  theoretically affect antibody  binding to  the  antigen  and   
Figure 7.4 In vitro peptide-specific T cell expansion. 
Peptide-specific T cells from HLA-typed, healthy blood donors 
were in vitro expanded from PBMCs using bi-weekly stimulation 
with peptide-loaded antigen-presenting cells. (a) Flow cytometric 
analysis of peptide-specific CD8+ T cells in freshly isolated 
PBMCs and (b) after in vitro culture for 7, 13, 27 and 30 days. 
Here, EBV_CLG peptide-specific CD8+ T cells were analyzed 
after gating on CD3+CD4-CD8+ cells, as depicted in Figure 7.3.  




Figure 7.5 Phenotypic characterization of in vitro expanded, peptide-specific T cells. 
(a) Flow cytometric analysis of freshly isolated PBMCs or (b) 22 days in vitro expanded T cells for 






Figure 7.6 Functional characteri-
zation of in vitro expanded, 
peptide-specific CD8+ T cells. 
(a) IFNγ ELISPOT assay using 
5x103 MDA-MB231 tumor cells as 
targets and 500 in vitro expanded, 
EBV_CLG-specific CD8+ T cells as 
responders. Cells were either 
treated with 1μM EBV_CLG 
peptide (pEBV_CLG) or left 
untreated. (b) Analysis of IFNγ 
ELISPOT assays with the same 
setup as in (a), but using different 
HLA-A2- (light grey) or HLA-A2+ 
tumor cell lines (dark grey) as 
targets. All graphs represent mean 
of replicates (n=3) and error bars 
indicate standard deviation. 
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internalization of complexes, ATPPs were tested in FACS to confirm target specificity 
and to compare the kinetic of the internalization process to the parental antibodies. 
Along this line, we pulsed CDCP1-expressing MDA-MB231 tumor cells with the 
EBV_CLG peptide-conjugated αCDCP1-CLG ATPP or the corresponding 
unconjugated αCDCP1 antibody (Ab), which were subsequently stained with 
fluorescently labeled αIgG Abs. Flow cytometric analysis revealed no difference in 
antigen binding (Figure 7.7a). In line with these results, we also detected comparable 
internalization rates between ATPP conjugate and parental antibody (Figure 7.7b, c). 
In detail, both compounds exhibited rapid internalization reaching 50% after 2 hours 
and approximately 90% after 23 hours (Figure 7.7d). 
  
 
Figure 7.7 ATPP binding to the target and internalization. 
(a) Flow cytometric analysis of αCDCP1 antibody (Ab) and ATPP binding to the target on MDA-
MB231 cells using a FITC-labeled secondary antibody. (b) Internalization of the αCDCP1-CLG ATPP 
or (c) the αCDCP1 Ab. MDA-MB231 cells were pulsed with Ab or ATPP and incubated for indicated 
time points at 4°C (black) or 37°C (grey). Non-internalized antibodies were subsequently detected by 
means of a FITC-labeled secondary antibody. (d) Percentage of internalization of αCDCP1 Ab (dark 
grey) and ATPP (light grey) as calculated from (b) and (c). 
 
 
7.5. ATPP treated tumor cells mediate efficient T cell activation in a TCR and 
target-dependent manner  
In the following we investigated whether ATPP loaded tumor cells could trigger 
activation of previously expanded, peptide-specific CD8+ T cells in vitro. For this 
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purpose, MDA-MB231 cells were loaded with ATPP or control compounds for 6 or 24 
hours, challenged with T cells and monitored for IFNγ release. While the native 
αCDCP1 Ab did not exhibit any effect, the αCDCP1-CLG ATPP triggered significant 
T cell activation at 13.2 and 1.32nM, corresponding to 2 and 0.2μg/mL (Figure 7.8a, 
b). Similarly to the unconjugated control Ab, a non-cleavable ATPP construct, where 
the peptide was conjugated via  a thioether  instead of a  disulfide  bond, showed  no  
 
Figure 7.8 ATPP-mediated T cell activation in a target-dependent manner. 
(a-c) IFNγ ELISPOT assay using 5x103 MDA-MB231 tumor cells as targets and 200 in vitro 
expanded, EBV_CLG-specific CD8+ T cells as responders. Cells were treated for 6 (light grey) or 24 
hours (dark grey) with indicated substances prior to T cell addition. In addition to the CDCP1-targeting 
ATPP carrying the EBV_CLG peptide (αCDCP1-CLG ATPP), tumor cells were treated with a non-
cleavable thioether construct or ATPPs targeting CD138, CD22 or CD79b proteins. Free peptide 
(pEBV_CLG) served as reference and αCDCP1 antibody (Ab) carrying no peptides as control. (b, c) 
Indicated values were generated by multiplying spot count, mean spot size and mean spot intensity 
per well. (d) IFNγ ELISA using 1.5x104 HCT-116 (black) or MDA-MB231 (grey) tumor cells as targets 
and 4.5x104 EBV_CLG-specific CD8+ T cells as responders. Cells were pre-treated for 24 hours with 
indicated substances and IFNγ was quantified 24 hours after T cell addition. All graphs represent 
mean of replicates (n=3) and error bars indicate standard deviation. 
 
effect, in turn highlighting that disulfide-dependent peptide release is important for 
ATPP functionality. Interestingly, free peptide mediated strikingly lower T cell 
activation, requiring 1.32μM to achieve comparable signals. Though, while free 
peptide generated similar responses regardless of incubation time, the ATPP effect 
increased remarkably when incubating tumor cells with the conjugates for 24 
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compared to 6 hours. These data suggest that, although transfer of introduced 
peptides onto MHC molecules seems to occur more efficiently in endosomes, the 
entire ATPP-mediated loading process requires more time than external loading of 
MHC molecules with free peptides. This effect is however reasonable, as the 
supposed action of ATPPs involves binding to the target, target internalization, 
endosomal peptide release and transfer onto MHC molecules, as well as recycling of 
MHC-peptide complexes to the cell surface.  
 
 
Figure 7.9 Expression of targets and control targets. 
(a-c) Flow cytometric analysis of CD138 expression on MDA-MB231 or (d-f) U266B1 cells using the 
antibody clone DL101, the clone MI15, the αCD138-CLG ATPP or the respective cold αCD138 
antibody (Ab). (g) Binding of the αCD22- or (h) the αCD79b-CLG ATPP on MDA-MB231 cells. 
Binding of ATPPs or respective cold Abs was visualized by means of a FITC-labeled αIgG secondary 
antibody. Isotype-matched control antibodies were used to compensate for Fc-mediated antibody 
binding. 
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Next, we sought to investigate target specificity of the ATPP approach. Hence, we 
generated pEBV_CLG-conjugated ATPPs against hematological targets that are 
supposed to be not expressed on MDA-MB231 breast cancer cells. Expectedly, both 
αCD22-CLG as well as αCD79b-CLG ATPPs did not trigger T cell activation (Figure 
7.8c). However, surprisingly the CD138-targeting conjugate exhibited even stronger 
effects than the αCDCP1-CLG ATPP. Thus, we analyzed target expression by flow 
cytometry. Interestingly, we could not detect CD138 expression on MDA-MB231 
cells (Figure 7.9a), while the U266B1 multiple myeloma cell line serving as positive 
control showed obvious staining for the antibody clone DL101 (Figure 7.9d).  
Nevertheless, when using the MI15 clone, we observed substantial expression in 
both cell lines (Figure 7.9b, e). Therefore, we analyzed target expression with the 
respective ATPP antibodies and subsequent detection by means of fluorescently 
labeled αIgG Abs in the following. In this setting, we detected clear binding of the 
αCD138-CLG ATPP on MDA-MB231 and U266B1 cells (Figure 7.9c, f), while both 
the αCD22-CLG as well as the αCD79b-CLG ATPP showed no considerable staining 
on MDA-MB231 cells (Figure 7.9g, h), in turn explaining the ELISPOT results. The 
ELISPOT data could be readily reproduced by IFNγ ELISA using MDA-MB231 and 
HCT-116 cells (Figure 7.8d). 
As we could barely detect a reduction in the ATPP effect upon dilution from 13.2 to 
1.3nM in the former assays, we next performed a titration of all generated ATPP 
constructs in previously selected cell lines. When using αCDCP1 ATPPs carrying the 
HLA-A2 restricted pEBV_CLG or pEBV_GLC peptides, we consistently detected a 
very low if any effect dilution from 13.2 to 0.132nM with HLA-A2+ MDA-MB231, HCT-
116 and A-375 cells (Figure 7.10a-c, e-g). Intriguingly, A-375 melanoma cells, which 
exhibit very low CDCP1 expression (Figure 7.2, Table 7.1), showed comparable 
results. Though, the effect completely disappeared in all cell lines upon dilution to 
0.0132nM, suggesting saturation of the system until a certain concentration between 
0.132 and 0.0132nM. When using the HLA-A1 restricted pINF_CTEL peptide, we 
observed similar results despite a small effect remaining at 0.0132nM with 
investigated HLA-A1+ HCT-116, A-375, BxPC-3 and PC-3 cells (Figure 7.11). 
However, αCDCP1-CTEL ATPPs exhibited higher peptide-loading rates, carrying 
5.35 peptides per Ab, while αCDCP1-CLG and αCDCP1-GLC ATPPs had 1.38 and 
1.83 peptides bound, respectively (Supplemental Figure 9.1d). As suggested in 
previous experiments, free peptide exhibited similar effects at 1,320nM compared to 
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13.2 - 0.132nM ATPP. Considering the average peptide labeling rate of e.g. 1.38 
peptides per Ab for the αCDCP1-CLG conjugate, the lowest concentration 
corresponds to  a  >7200-fold difference in  the amount of peptide required  to elicit a  
 
 
Figure 7.10 Dose-dependency of the ATPP approach using HLA-A2 restricted EBV-derived peptides. 
IFNγ ELISA using 1.5x104 HLA-A2+ tumor cells as targets and 4.5x104 in vitro expanded, peptide-
specific CD8+ T cells as responders. (a-c) MDA-MB231, HCT-116 or A375 cells were treated with the 
HLA-A02:01-binding EBV_CLG peptide (pEBV_CLG), the control αCDCP1 antibody (Ab) or the 
αCDCP1-CLG ATPP. (d) CD138 was chosen as target in U266B1 cells. (e-g)  The HLA-A02:01-
binding EBV_GLC peptide was used instead of the EBV_CLG peptide. Cells were pre-treated for 24 
hours with indicated substances and IFNγ was quantified 24 hours after T cell addition. All graphs 
represent mean of replicates (n=3) and error bars indicate standard deviation. 
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similar T cell response by free peptide versus ATPP. As already proven for MDA-
MB231 cells, targeting the cell surface proteoglycan CD138 (Syndecan-1) on 
U266B1 cells exhibited comparable efficacy (Figure 7.10d), thus proving 
transferability of the ATPP approach to other cancer targets. 
In order to ensure that the ATPP-mediated IFNγ release derives from T cell 
activation upon TCR interaction with the cognate MHC-peptide complex, we next 
tried to block the MHC accessibility by means of an HLA binding antibody. 
Expectedly, adding the antibody clone W6/32, which binds to conserved residues on 
α1 and α2 domains of HLA-A, B and C molecules, abolished T cell activation in a 
concentration-dependent manner for both MDA-MB231 and A375 cells (Figure 7.12).  
 
 
Figure 7.11 Dose-dependency of the ATPP approach using an HLA-A1 restricted influenza-derived 
peptide. 
IFNγ ELISA using 1.5x104 HLA-A1+ tumor cells as targets and 4.5x104 in vitro expanded, peptide-
specific CD8+ T cells as responders. (a) HCT-116, (b) A375, (c) BxPC-3 or (d) PC-3 cells were 
treated with the HLA-A01:01-binding INF_CTEL peptide (pINF_CTEL), the control αCDCP1 antibody 
(Ab) or the αCDCP1-CTEL ATPP. Cells were pre-treated for 24 hours with indicated substances and 
IFNγ was quantified 24 hours after T cell addition. All graphs represent mean of replicates (n=3) and 
error bars indicate standard deviation. 
 
7.6. Virus-specific CD8+ T cells efficiently kill ATPP treated tumor cells in vitro 
After demonstrating that ATPP loaded tumor cells potently trigger activation of 
peptide-specific CD8+ T cells, we aimed at determining whether this activation also 
mediates lysis of target cells. As ATPP conjugates did not exhibit a titration-
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dependent efficacy reduction from 13.2 to 0.132nM in the previous experiments, we 
primarily focused on the 0.132nM concentration as the minimum effective dose 
(MED) in the following. Along this line, treatment of both MDA-MB231 and HCT-116 
cells with the αCDCP1-CLG ATPP resulted in efficient killing of tumor cells starting at 
an effector-to-target (ET) ratio of 1:1, as detected by lactate dehydrogenase (LDH) 
release in the supernatant (Figure 7.13a). Importantly, an ET-ratio of 3:1 was 




pletely lysed when using 12 T cells per tumor cell. In line with previous results, a 
1000-fold higher concentration of free peptide was less efficient and the non-
targeting αCD22-CLG ATPP showed no effect.  
In order to investigate the kinetic of the killing process, we made use of the 
xCELLigence system, which allows continuous monitoring of target cell lysis via 
impedance measurement of adherent tumor cells. As MDA-MB231 cells generated 
too low cell indices, we concentrated on the HCT-116 cell line in this respect. Using 
an ET-ratio of 3:1, the αCDCP1-CLG ATPP triggered rapid lysis of tumor cells after T 
cell addition, leading to >60% of killing within the first 6 hours, while the residual 
Figure 7.12 Dependency on MHC-TCR 
interaction of the ATPP approach. 
IFNγ ELISA using 1.5x104  HLA-A2+ tumor 
cells as targets and 4.5x104 in vitro 
expanded, EBV_CLG-specific CD8+ T cells 
as responders. (a) MDA-MB231 or (b) 
A375 cells were treated with indicated 
concentrations of the CDCP1-targeting 
ATPP carrying the EBV_CLG peptide. After 
24 hours different concentrations of the 
HLA-binding antibody clone W6/32 were 
added prior to T cells. IFNγ was quantified 
24 hours after T cell addition. All graphs 
represent mean of replicates (n=3) and 
error bars indicate standard deviation. 
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killing took place during the following 18 hours (Figure 7.13b, c). As before, a 1000-
fold higher concentration of free peptide showed inferior efficacy and non-targeting 
as well as non-cleavable controls exhibited no effects. These results were 
additionally confirmed by applying time-lapse live-cell imaging. In this context, 
addition of the αCDCP1-CLG ATPP induced serial killing of HCT-116 cells by 
peptide-specific CD8+ T cells, while T cells did not attack tumor cells treated with the 
CD22-targeting ATPP (Figure 7.14). 
 
 
Figure 7.13 ATPP-mediated tumor cell killing by peptide-specific CD8+ T cells. 
(a) LDH release assay using 1.5x104 MDA-MB231 (top) or HCT-116 cells (bottom) as targets and in 
vitro expanded, EBV_CLG peptide-specific CD8+ T cells as effectors. Tumor cells were pre-treated for 
24 hours with substances and T cells were added at indicated effector-to-target ratios. LDH was 
quantified after 24 hours in the supernatant and used to calculate tumor cell lysis. (b) Real-time 
analysis of target cell killing by the xCELLigence system using HCT-116 cells, which were previously 
incubated 24 hours with indicated substances. EBV_CLG-specific CD8+ T cells (E-T ratio 3:1) were 
added at t=0. (c) Percentage of tumor cell killing was calculated with data received from (b) at 
indicated time points. In addition to the CDCP1-targeting ATPP carrying the EBV_CLG peptide, tumor 
cells were treated with free peptide (pEBV_CLG), a non-cleavable thioether construct or the CD22-
targeting ATPP as control. All graphs represent mean of replicates (n=3) and error bars indicate 
standard deviation. 
 




Figure 7.14 Time-lapse imaging of ATPP-mediated tumor cell killing. 
Time-lapse confocal microscopy of HCT-116 cells (green, CMFDA) being killed by in vitro expanded, 
EBV_CLG peptide-specific CD8+ T cells (red, PKH-26) upon ATPP treatment. Tumor cells were pre-
treated for 24 hours with 0.132nM αCDCP1-CLG ATPP or the control αCD22-CLG ATPP, stained and 
after T cell addition subjected to optical imaging for indicated time points. Scale bar: 20μm. Data were 
generated in collaboration with Heike Seul (Large Molecule Research, Roche Diagnostics GmbH, 
Penzberg). 
 
7.7. ATPP delivered peptides are released in endosomes and do not enter the 
classical MHC class I antigen processing pathway 
Having proven the functionality of generated ATPP immunoconjugates, we aimed at 
clarifying the underlying mode of action in the following. First, we wanted to 
determine where exactly peptide release does occur. Based on the technique used 
by Yang and colleagues191 we generated an ATPP reporter construct, which allows 
visualization of disulfide bond cleavage by fluorescence resonance energy transfer 
(FRET) technology. As depicted in Figure 7.15a, the reporter molecule consisted of a 
linker peptide, which was covalently bound to the αCDCP1 Ab and served as a 
backbone for fluorophore attachment. The FRET donor BODIPY was linked to the 
peptide via an amide bond, while the acceptor rhodamine was conjugated via a 
reducible disulfide bond, in turn serving as a mimic for the releasable peptide in 
ATPP immunoconjugates. When the disulfide bond is intact, excitation of BODIPY at 
488nm results in intramolecular energy transfer to rhodamine and emission of red 
light (Figure 7.15a). Upon disulfide reduction, rhodamine is released from the 
conjugate, resulting in the loss of FRET, in turn generating a green (BODIPY) signal 
(Figure 7.15b). Using this construct we monitored the spatiotemporal peptide release 
by live-cell imaging (Figure 7.16). As shown in Figure 7.16a, peptide release 
occurred in  endosomes  as  revealed by green BODIPY signals at  t = 2 hours, while  





only red FRET signals could be detected at the cell surface at t = 0. Green 
background signals may derive from incomplete FRET efficacy, which was about 
90% (data not shown). Green fluorescence increased upon proceeding incubation 
time, suggesting accumulation of cleaved constructs. Importantly, separate excitation 
of the acceptor rhodamine revealed its release into the endosomal lumen, while the 
BODIPY donor remained membrane bound (Figure 7.16b). This finding confirmed 
that separation of the donor and the acceptor did not derive from proteolytic 
digestion, but from disulfide-dependent release of the acceptor from the conjugate. 
Co-localization of the donor and the antibody backbone (Figure 7.16c) additionally 
confirmed this finding and showed that the backbone was still intact.  
In order to prove the postulated mode of action of ATPPs comprising the exchange 
of self-peptides on MHC class I complexes for delivered viral peptides in the 
endosomal compartment, we generated an extended EBV_CLG peptide by N-
terminally elongating the peptide by the natural 6 amino acids of the LMP2 protein, in 
turn generating the EBV_YGP peptide (Table 6.1). In order to be presented on MHC 
class I, this peptide would require classical antigen processing, e.g. trimming by 
endoplasmic reticulum (ER)-associated aminopeptidases 1 and 2 (ERAP1/2) in the 
ER, in order to generate pEBV_CLG-MHC complexes. When performing IFNγ ELISA 
or LDH release assays with MDA-MB231 or HCT-116 cells, we realized that – in 
Figure 7.15 Schematic and 
functional illustration of the CDCP1-
FRET reporter molecule. 
The CDCP1-FRET reporter was 
generated by conjugating a BODIPY 
(green) linked peptide sequence to 
the C-terminus of the αCDCP1 
antibody, while a Rhodamine 
fluorophore (red) was linked via a 
disulfide bond to a cysteine on the 
same peptide. (a) Excitation of the 
BODIPY fluorophore results in FRET 
from BODIPY to rhodamine and 
subsequent rhodamine (red, 595nm) 
emission. (b) Upon disulfide 
reduction, rhodamine is released 
from the conjugate, in turn allowing 
BODIPY (green, 520nm) emission. 
The CDCP1-FRET molecule was 
generated in the laboratory of Lars 
Hillringhaus (Peptide Chemistry, 
Roche Diagnostics GmbH, 
Penzberg). The figure was modified 
after adaption from Yang et al.191  
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contrast to the EBV_CLG peptide – neither free EBV_YGP peptide, nor the 
αCDCP1-YGP ATPP triggered T cell activation or lysis of tumor cells (Figure 7.17), 
in turn confirming that ATPP-delivered peptides do not enter the classical MHC class 
I antigen processing and presentation pathway.  
 
 
Figure 7.16 Endosomal disulfide reduction visualized by FRET. 
FRET confocal microscopy using MDA-MB231 cells. (a) Tumor cells were pulsed with the αCDCP1-
FRET construct and analyzed for BODIPY (upper channel) and rhodamine (FRET, lower channel) 
emission after BODIPY excitation at 488nm by confocal microscopy at t=0, 2, 18h. (b) Endosome of a 
tumor cell 2h after pulsing with the FRET construct. Excitation and emission of the donor (BODIPY, 
upper channel) as well as separate excitation and emission of the acceptor (rhodamine, lower 
channel) is shown. (c) Higher magnification of an endosome 2h after pulsing with the FRET construct. 
Detection of the αCDCP1 Ab by a secondary Ab (αIgG Ab) in addition to the donor and acceptor 
signals. Data were generated in collaboration with Doris Ziegler-Landesberger (Large Molecule 
Research, Roche Diagnostics GmbH, Penzberg). 
 
7.8. Peripheral blood peptide-specific CD8+ T cells respond to ATPP treatment 
and efficiently kill ATPP treated tumor cells in vitro 
Previous data revealed the potential of ATPPs as efficient treatment against multiple 
cancer types, provided that the constructs do trigger activation of the corresponding 
peptide-specific memory T cells. In the former experiments we utilized T cell cultures 
that had been expanded in vitro to achieve higher frequency of peptide-specific cells. 
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In the following, we used freshly isolated PBMCs from human blood, in order to show 
ATPP induced activation of pre-existing circulating virus-specific T cells without 
culture-depended reactivation and propagation. PBMCs were simply enriched for 
CD8+ T cells by negative selection, in order to reduce alloreaction-derived 
background signals. Analyzing the sort purity by flow cytometry revealed that 97.3% 
of the obtained CD3+ T cell population were CD8+, whereof 0.52% recognized the 
EBV_CLG peptide (Figure 7.18a). In line with previous results, ATPP loaded MDA-
MB231 cells triggered activation of freshly isolated, non-expanded T cells, while 
controls showed no signals (Figure 7.18b). Remarkably, despite the low frequency of 
pEBV_CLG-specific T cells resulting in an ET-ratio of 1:10, >20% of target cells 
treated with 0.132nM αCDCP1-CLG ATPP were lysed after 24 hours (Figure 7.18c).  
 
 
Figure 7.17 Investigation of intracellular processing of ATPP-delivered peptides. 
(a, b) IFNγ ELISA or (c,d) LDH release assay using 1.5x104 MDA-MB231 or HCT-116 tumor cells as 
targets and 4.5x104 in vitro expanded, EBV_CLG peptide-specific CD8+ T cells as responders. Tumor 
cells were pre-treated for 24 hours with indicated concentrations of free peptide or the αCDCP1 ATPP 
carrying either the EBV_CLG (pEBV_CLG) or the EBV_YGP peptide (pEBV_YGP). The latter 
represents the EBV_CLG peptide that is N-terminally extended by the naturally occurring 6 amino 
acids of the LMP-2 protein. IFNγ or LDH was quantified 24 hours after T cell addition. For peptide 
sequences see Table 6.1. All graphs represent mean of replicates (n=3) and error bars indicate 
standard deviation. 




Figure 7.18 ATPP-mediated activation of freshly isolated, PBMC-derived CD8+ T cells. 
(a) Flow cytometric analysis of sort purity and abundance of peptide-specific T cells after 
RosetteSep™-mediated sorting of CD8+ T cells from human blood. (b) IFNγ ELISA or (c) LDH release 
assay using 1.5x104 MDA-MB231 tumor cells as targets and 3x105 CD8+ T cell enriched PBMCs as 
responders. Tumor cells were pre-treated for 24 hours with indicated substances and IFNγ or LDH 
was quantified 24 hours after T cell addition. In addition to the CDCP1-targeting ATPP carrying the 
EBV_CLG peptide, tumor cells were treated with free peptide (pEBV_CLG), a non-cleavable thioether 
construct or a CD22-/CD79b targeting ATPP as control. All graphs represent mean of replicates (n=3) 
and error bars indicate standard deviation. 
 
 
While these data show that peripheral peptide-specific memory T cells can kill ATPP 
loaded tumor cells, regression of an established tumor in patients would probably 
require expansion of the peptide-specific T cell pool. To address this question in 
vitro, we cultured PBMCs with varying concentrations of ATPPs targeting the B cell 
receptors CD22 or CD79b and monitored peptide-specific T cell expansion by flow 
cytometry using peptide-MHC pentamers. A representative analysis for the αCD22-
CLG ATPP is depicted in Figure 7.19b. While the frequency of peptide-specific CD8+ 
T cells rather declined over time in untreated culture medium, treatment with αCD22- 
or αCD79b-CLG ATPPs resulted in significant expansion of peptide-specific cells 
(Figure 7.19a). Interestingly, both ATPPs exhibited strikingly higher potential to 
trigger T cell expansion compared to free peptide, which only showed an effect at the 
highest concentration. Although both ATPPs displayed comparable efficacy at 13nM, 
targeting CD22 receptors seemed to be more efficient at lower concentrations. 




Figure 7.19 ATPP-mediated peptide-specific CD8+ T cell expansion by targeting B cell receptors. 
(a) EBV_CLG peptide-specific CD8+ T cell abundance as determined by flow cytometry, after 
culturing PBMCs with free EBV_CLG peptide (pEBV_CLG) or CD22- vs. CD79b-targeting ATPPs for 
indicated time. (b) Representative flow cytometric analysis of EBV_CLG peptide-specific CD8+ T cells 
in freshly isolated PBMCs (d0) and after in vitro culture for 13, 20 and 26 days with 13nM of the 
αCD22-CLG ATPP. EBV_CLG peptide-specific CD8+ T cells were analyzed after gating on CD3+CD4-
CD8+ cells, as depicted in Figure 7.3. 
 
7.9. Peptide-specific CD8+ T cells accumulate in tumors in response to ATPP 
treatment and trigger tumor cell killing in vivo 
In order to investigate the in vivo efficacy of ATPP treatment, we next performed a 
subcutaneous tumor xenograft study in NOG mice using the CDCP1+, HLA-A2+ 
MDA-MB231 breast cancer cell line. In the first experiment we decided to apply a 
preventive setting, where ATPP treatment was started at the day of tumor inoculation 
(Figure 7.20a). Of note, we used the αCDCP1-CLG ATPP with an IgG4 backbone, 
as IgG4 is known to not bind to FcγRs in humans. In vitro expanded, peptide-
specific, human T cell cultures served as effector cells and were transferred 
intravenously per mouse on day 1 and again on day 16. As survival of human T cells 
is critical in mice, we had chosen cultures with lower peptide-specificity and higher 
CD4+ T cell frequency to possibly support effector T cell survival. Hence, cultures 
were 79.1 or 84.3% CD8+ and only 18.1 or 26.7% peptide- specific. When monitoring  
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Figure 7.20 In vivo efficacy of the αCDCP1-CLG ATPP carrying an IgG4 backbone in a preventive 
xenograft tumor setting. 
(a) Overview of the study setup, using the MDA-MB231 s.c. breast cancer xenograft model in NOG 
mice and adoptive transfer of in vitro expanded, human EBV_CLG peptide-specific CD8+ T cells. 
5x106 MDA-MB231 cells were subcutaneously injected into the right flank of NOG mice. On day 1 and 
day 16 1x107 in vitro expanded, human T cells were adoptively transferred by intravenous injection 
into the tail vain. αCDCP1_IgG4-CLG ATPP and control αCDCP1_IgG4 Ab were administered 
intraperitonally, starting on d0. (b) Flow cytometric analysis of adoptively transferred T cells on d1 and 
(c) on day 16 prior to adoptive transfer. (d) Kinetic of MDA-MB231 tumor growth as determined by 
caliper measurement. Mice were either only injected s.c. with tumor cells (Tumor Control), additionally 
received i.v. T cells (T cell Control) and were additionally treated with αCDCP1_IgG4-CLG ATPP or 
the respective αCDCP1_IgG4 antibody (Ab) carrying no peptides as control. (e) Endpoint analysis of 
tumor volume on day 30. For each chart, data is shown as mean and error bars indicate standard 
error of mean (n=15, n=10 for T cell control). The p values represent comparisons between groups 
using one-way ANOVA followed by Turkey´s multiple comparison test. *p < 0.05, ** p < 0.01, ****p < 
0.0001, n.s.: not significant. 
 
tumor volume over time, we observed striking tumor growth inhibition for the 
αCDCP1_IgG4-CLG ATPP (Figure 7.20d), resulting in tumors with 94.5mm3 in 
average after 30 days, while mice only receiving tumor cells exhibited tumors with 
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averaged 249.2mm3 (Figure 7.20e). Adoptive transfer of T cells did not influence 
tumor growth (Tumor control vs. T cell control, not significant). Mice treated with the 
unconjugated αCDCP1_IgG4 Ab showed a prominent reduction in tumor volume, 
although still exhibiting significantly bigger tumors than ATPP treated animals (150.2 
vs. 94.5mm3, p<0.05). When monitoring the health status of the animals during the 
experiment, we realized a distinct reduction in body weight after day 30 in mice that 
had received T cell transfer (Figure 7.21a). Flow cytometric analysis of spleens 
(Figure 7.21b) and tumors (Figure 7.21c) on day 34 revealed massive infiltration of 
human T cells associated with a substantial expansion of the CD4+ T cell population, 
suggesting an ongoing graft-versus-host disease (GvHD). In accordance with animal 
welfare guidelines the experiment was terminated and tumor volumes were only 




Figure 7.21 Emergence of graft-versus-host disease in 
mice receiving adoptive transfer of human T cells. 
(a) Kinetic of body weight of NOG mice that were either 
only injected s.c. with tumor cells (Tumor Control), 
additionally received i.v. T cells (T cell Control) and were 
additionally treated with αCDCP1_IgG4-CLG ATPP or 
the respective αCDCP1_IgG4 antibody (Ab) carrying no 
peptides as control. Data is shown as mean (n=15, n=10 
for T cell control) and error bars indicate standard error 
of mean. (b) Representative flow cytometric analysis of 
human T cells in spleens and (c) tumors of “T cell 
control” mice on study day 35. 




Figure 7.22 In vivo efficacy of the Fc-binding depleted αCDCP1-CLG ATPP in combination with αPD1 
treatment using a therapeutic xenograft tumor setting. 
(a) Overview of the study setup, using the MDA-MB231 s.c. breast cancer xenograft model in NOG 
mice and adoptive transfer of in vitro expanded, human EBV_CLG peptide-specific CD8+ T cells. 
5x106 MDA-MB231 cells were subcutaneously injected into the right flank of NOG mice. When tumors 
reached approximately 70mm3, mice were i.p. injected with 20mg/kg/week of αCDCP1-CLG ATPP or 
the respective control αCDCP1 Ab, consisting of an IgG1 backbone with the P329G LALA mutation 
for abolished Fc-receptor binding. On day 22, 5x106 in vitro expanded, human T cells were adoptively 
transferred by intravenous injection into the tail vain. (b) Flow cytometric phenotyping of adoptively 
transferred T cells prior to transfer according to peptide specificity and CD4, CD8 and PD1 
expression. (c) Analysis of target (CDCP1) and PD-L1 expression in s.c. MDA-MB231 tumors by flow 
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cytometry. (d) Kinetic of MDA-MB231 tumor growth as determined by caliper measurement. Mice 
were either only injected s.c. with tumor cells (Tumor Control), additionally received i.v. T cells (T cell 
Control) and were treated with αCDCP1-CLG ATPP or αCDCP1 antibody (Ab) carrying no peptides 
as control, as well as with αPD1 Ab. (e) Endpoint analysis of tumor volume on day 39. (f) Analysis of 
tumor weight on day 40. (g) Correlation of tumor weight (d40) and tumor volume (d39). r2: coefficient 
of determination. For charts d-f, data is shown as mean and error bars indicate standard error of 
mean (n=10). The p values represent comparisons between groups using one-way ANOVA followed 
by Turkey´s multiple comparison test. ** p < 0.01, ***p < 0.001. 
 
As the observed effect of the αCDCP1 Ab possibly derived from the human IgG4 
backbone, which – despite its inert phenotype in the human system – can bind to all 
murine FcγRs196, we utilized the αCDCP1-CLG ATPPs with the P329G LALA-
mutated IgG1 backbone, as previously used in vitro. Since the results from the initial 
animal study demonstrated first hints for anti-tumor efficacy of ATPPs in vivo, we 
next evaluated the therapeutic effect of ATPP treatment by using the same xenograft 
model but with established tumors (Figure 7.22a). For this purpose, mice were 
staged on day 20 according to tumor volume (70mm3) and subsequently treated with 
the αCDCP1-CLG ATPP or the control Ab. Human, peptide-specific T cells were 
adoptively transferred on day 22. Due to the GvHD observed in the former study, 
were used cultures that were 93.1% CD8+ and 88.6% peptide-specific (Figure 
7.22b). Due to the extended expansion period and repeated antigenic stimulations 
required to achieve higher frequency of peptide-specific T cells, CTLs exhibited a 
PD1+ phenotype. As MDA-MB231 tumor cells simultaneously expressed high levels 
of PD-L1 in vivo (Figure 7.22c), we additionally included αPD1 Ab treatment. When 
monitoring tumor volume over time, we observed substantial tumor growth inhibition 
in αCDCP1-CLG ATPP treated animals until day 32 (Figure 7.22d). However, tumors 
started to resume exponential growth after that time point. On day 39 there was no 
significant difference between tumor control (312.8mm3), T cell control (333.1mm3) 
and ATPP only-treated mice (270.2mm3, Figure 7.22e). In contrast, animals 
receiving ATPP in combination with αPD1 treatment exhibited a striking and 
sustained delay in tumor growth until the end of the study (175.1mm3), while the 
combination of αPD1 treatment with αCDCP1 Ab therapy did not show any effect 
(317.7mm3, p<0.01). Based on these data, combined ATPP and αPD1 treatment 
accounted for 58.4% tumor growth inhibition at the end of the study. Analysis of 
tumor weights after necropsy revealed comparable results (Figure 7.22f), though 
showing   imperfect  correlation  to  tumor   volumes  (r2=0.51,  Figure  7.22g),  which  




Figure 7.23 Analysis of adoptively transferred human T cells in tumors and spleens of mice. 
(a) Representative flow cytometric analysis of adoptively transferred T cells in tumors and (b) spleens 
according to peptide-specificity using peptide-MHC pentamers. (c) Combined analysis of EBV_CLG 
peptide-specific CD8+ tumor infiltrating lymphocytes (TILs) in s.c. MDA-MB231 tumors on day 40 in 
mice either only injected with tumor and T cells (T cell Control) or additionally treated with αCDCP1-
CLG ATPP or αCDCP1 antibody (Ab) carrying no peptides as control, as well as with αPD1 Ab. (d) 
Combined analysis of EBV_CLG peptide-specific CD8+ T cells in spleens on day 40. (e) Kinetic of 
body weight of NOG mice in the study. For each chart, data is shown as mean and error bars indicate 
standard error of mean (n=10). The p values represent comparisons between groups using one-way 
ANOVA followed by Turkey´s multiple comparison test. ****p < 0.0001. 
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possibly derived from the fact that MDA-MB231 tumors developed necrotic areas 
very early. When analyzing tumors (Figure 7.23a) and spleens (Figure 7.23b) by flow 
cytometry, we could not detect abnormal T cell expansion as observed in the 
previous study, suggesting no GvHD associated problems, as additionally confirmed 
by consistent body weight development in all treatment groups (Figure 7.23e). 
Though importantly, we detected a striking increase in EBV_CLG peptide-specific 
tumor infiltrating lymphocytes (TILs) in the group treated with ATPP and αPD1 Ab 
(Figure 7.23c), suggesting enhanced tumor infiltration, proliferation or survival of 
peptide-specific T cells in this setting, while there was no difference observed in the 
spleen (Figure 7.23d). 
 
In summary, these results show that ATPP immunoconjugates can selectively deliver 
immunogenic peptides to tumor cells, in turn triggering activation of peptide-specific 
effector memory T cells, which are able to mediate tumor cell lysis in vitro and in 
vivo. 




The aim of this thesis was to generate immunoconjugates that selectively deliver 
virus-derived, immunogenic MHC-I peptide epitopes to cancer cells via a tumor 
antigen-specific antibody for the induction of tumoricidal, T cell-mediated cytotoxicity. 
Our results show that these antibody-targeted pathogen-derived peptides (ATPPs) 
efficiently release the peptides in endosomal compartments of tumor cells. Upon 
loading into cellular MHC complexes, these peptides triggered activation of peptide-
specific CTLs and subsequent killing of various cancer cell lines in vitro. In vivo, 
therapeutic ATPP treatment generated significant anti-tumor effects in the 
subcutaneous MDA-MB231 breast cancer xenograft model with adoptive transfer of 
in vitro expanded, human, peptide-specific T cells, especially when combined with 
αPD1 Ab therapy. These findings may have substantial importance with respect to 
the development of novel immunotherapies. 
 
8.1. Therapeutic implications of ATPP immunoconjugates and suggestions for 
further pre-clinical experimentation 
Immune tolerance is a major reason for the ineffectiveness of the anti-cancer 
immune response as well as for the failure of cancer immunotherapies that exploit 
the endogenous T cell repertoire (e.g. checkpoint inhibition or adoptive transfer of 
TILs)59,60. The usefulness of T cells for recognition of self-peptides presented on self-
MHCs is restricted by tolerance conferred during thymic development. As a result, 
antigen-specific T cell responses are limited to cancers with high numbers of non-
synonymous mutations that generate immunogenic neo-epitopes. Hence, the 
therapeutic application of ATPPs seems particularly feasible for conferring 
immunogenicity to cancers with low mutational load, where checkpoint inhibitor 
therapy fails. Besides, targeting of cancer antigens (e.g. by cancer vaccination 
therapies) often requires simultaneous interference with peripheral tolerance 
mechanisms (such as depletion of Tregs) that additionally prevent effective immunity 
against tumor antigens197,198. Therefore, checkpoint inhibitor therapy may be applied 
after introduction of ATPP-delivered antigens, in order to counteract peripheral 
immune tolerance and immunosuppression that might prevent efficient T cell 
responses. 
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Importantly, immune tolerance mechanisms also play a decisive role in tumors with 
high numbers of non-synonymous somatic mutations. Although exhibiting higher 
immunogenicity, productive T cell responses are rarely observed in these patients61. 
Therefore, overcoming immune tolerance against already pre-existing antigens 
represents a major objective of cancer immunotherapy. Along this line, ATPPs 
exploit the endogenous, virus-specific high affinity T cell repertoire, in contrast to e.g. 
adoptive cellular therapies infusing ex vivo expanded tumor-reactive TILs. The 
potential of viral epitopes in mediating tumor rejection is well known199 and 
additionally highlighted by the high abundance of virus-induced cancers in 
immunosuppressed patients200. As the tumoricidal T cells exploited by ATPP 
treatment target foreign, virus-derived antigens, there´s no potential for auto-
reactivity. Hence, the endogenous T cell repertoire could additionally be boosted by 
vaccination prior to treatment. Furthermore, vaccination could be applied to replenish 
the effector T cell pool after a first round of therapy, e.g. when CTLs have become 
exhausted or tolerized in the tumor microenvironment. 
ATPP therapy may especially qualify to avoid cancer progression after an initial 
response to checkpoint inhibition, that might result from the emergence of escape 
variants with reduced immunogenicity. In general, combined treatment with 
checkpoint inhibitors seems reasonable to support proper T cell function at the tumor 
site. Especially cancers with increased mutational burden are known to generate a 
highly immunosuppressive microenvironment that may hamper even high affinity T 
cell responses.   
The beneficial potential of combining checkpoint inhibitors with ATPP treatment has 
been distinctly proven in vivo, resulting in 60% tumor growth inhibition. While the 
utilized model seems to perfectly qualify for investigating the possibility to combine 
ATPP with αPD1 treatment (high PD-L1 expression on MDA-MB231 and high PD1 
expression on transferred T cells), it has several drawbacks in elucidating the 
achievable anti-tumor effect of ATPPs. Clearly, T cell function and/or survival are 
obviously hampered by PD1/PD-L1 interaction and it remains to be elucidated 
whether the applied αPD1 therapy can completely abolish this impediment. In 
addition, adoptively transferred T cells exhibited an exhausted phenotype due to 
repeated stimulation with antigen in culture, as evidenced by high PD1 expression 
and inferior cytolytic capacity in vitro compared to freshly isolated T cells. 
Furthermore, despite in vitro T cell expansion supported by IL-15 in the absence of 
REFERENCES  78 
 
 
IL-2, which entails better survival and activity of human memory T cells in mice201,202, 
survival, functionality and especially expansion of these cells are hampered in a 
xenogeneic host. These limitations may explain the lacking efficacy of ATPP 
monotherapy at the end of the study, whereas TILs were probably present and active 
at earlier time points, as suggested by the obvious effect of ATPP treatment in the 
beginning (Figure 7.22). Hence, the implementation of a syngeneic model with 
unimpaired T cell functionality seems reasonable. In such a setting we would expect 
more robust tumoricidal responses, as memory T cells typically undergo rapid 
population expansion upon antigen re-challenge. Moreover, it excludes the 
possibility of graft-versus-host reactions, in turn allowing extended therapy and 
monitoring. Importantly, the utilization of a syngeneic mouse model would 
additionally enable the investigation of vaccination as an approach to boost the T cell 
repertoire employed by ATPPs.  
In general, the simplest model with respect to the generation of the antigen-specific 
T cell repertoire would involve the adoptive transfer of peptide-specific T cells from 
TCR-transgenic mice. In this respect, the use of OT-I mice in combination with the 
(OVA)-deduced SIINFEKL peptide as antigen seems most feasible, as this system 
would also allow investigation of ATPP-mediated peptide delivery via detection of 
MHC-peptide complexes on the cell surface of tumor cells by means of the 25-D1.16 
antibody203. Nevertheless, this model would utilize naïve instead of effector memory 
cells. Hence, OVA-specific immunization may be applied in immunocompetent 
C57BL/6 mice to generate and also boost the effector T cell pool. The vaccination 
strategy would imply the generation of memory T cells in the course of an immune 
response and hence better recapitulate the clinical situation. To achieve the clinically 
most authentic situation, we suggest to utilize a syngeneic model based on acute or 
chronic viral infection such as the Lymphochoriomeningitis Virus (LCMV) model used 
by Cesson et al.204. This setup would probably generate the most physiologic T cell 
repertoire in terms of cell numbers and functionality and additionally allow assessing 
the impact of vaccination-based amplification of the antigen-specific T cell pool at 
any point of the treatment.  
 
8.2. Comparison to similar formulations 
Up to date, various efforts have been made to deliver viral antigens to tumor cells, in 
order to redirect virus-specific T cells against cancer, thereby exploiting their high 
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affinity TCRs. Along this line, several groups have generated targeted peptide-MHC 
tetramers by conjugating MHC molecules containing viral peptides to tumor antigen-
specific antibodies by means of the biotin-streptavidin system205-208. Specific delivery 
to tumor-associated CD20, CEA or ErbB-2 surface antigens resulted in efficient 
target cell lysis by peptide-specific CTLs in vitro. Nevertheless, the large molecular 
mass (>400kDa) of these conjugates prevents effective tissue penetration, hence 
limiting their in vivo applicability. Besides, streptavidin is a highly immunogenic 
protein209 that may favor the generation of anti-drug antibodies as well as the 
induction of immune-related adverse effects. 
In order to overcome these limitations, targeted peptide-MHC fusions have been 
generated as fully recombinant molecules. These consist of a tumor antigen 
targeting binding moiety, either antibody or antibody-derived fragment, and a 
covalently linked MHC class I molecule containing the immunogenic peptide epitope. 
Various peptide-MHC fusions have already proven significant anti-tumor effects in 
vitro210-214.  For instance, Schmittnaegel and colleagues have successfully generated 
a fusion molecule with a full length IgG1 backbone214. By using the immunodominant 
pp65 peptide epitope from the human Cytomegalovirus (CMV) they could efficiently 
induce lysis of various tumor cells in vitro by targeting differing surface antigens, 
including melanoma-associated chondroitin sulfate proteoglycan (MCSP). In vivo 
efficacy of those molecules could be shown when effector cells were co-engrafted 
with tumor cells and/or cancer cells were pre-loaded with the compound prior to 
implantation213-215. However, none of these molecules has yet advanced to clinical 
development. With respect to clinical applicability, the utility of peptide-MHC fusions 
is generally limited by their restriction to the patient population with corresponding 
HLA genotypes. In contrast, a major advantage of the ATPP concept represents the 
exploitation of cellular MHC complexes, hence not requiring sophisticated cloning 
and expression technologies. ATPPs are generated by biochemical conjugation, 
thereby allowing feasible production of multiple differing molecules.  
All of the aforementioned formulations have tried to trigger tumoricidal T cell activity 
by delivering mature MHC-peptide complexes to the tumor site. As a result, these 
functional entities can also directly bind to TCRs before reaching the target cells, e.g. 
in the bloodstream. Due to their structural design, MHC tetramers provide four sites 
for TCR engagement and thus can efficiently trigger activation of circulating T cells 
without binding to the tumor antigen, in turn resulting in significant off-target 
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toxicity216. In contrast, binding of peptide-MHC fusions is unlikely to mediate T cell 
activation due to imperfect TCR clustering. Yet, sub-threshold stimulation and the 
lack of co-stimulatory ligands may lead to T cell anergy150,217, in turn compromising 
the functionality of the T cell repertoire. On the other hand, delivery of full peptide-
MHC complexes has also certain advantages. For instance, it will overcome one of 
the major immune escape mechanisms of cancer cells that relies on the loss or 
downregulation of HLA molecules. In contrast, ATPPs depend on cellular MHC 
molecules and hence will allow outgrowth of clones that have lost expression of the 
respective HLA allotypes required for presentation of the delivered epitopes. 
In recent years, various technologies have emerged that – comparable to ATPPs – 
simply deliver immunogenic antigens to the target cell, where they require loading 
into cellular MHC complexes for eliciting a T cell response. In 2015, Yu and 
colleagues have generated antigen-armed antibodies by directly incorporating 
immunodominant T cell epitopes from EBV proteins into the antibody sequence218. 
By targeting the B cell surface receptors CD19-CD22 they efficiently delivered EBV 
antigens into lymphoma cells in vitro, thereby triggering activation of antigen-specific 
CD4+ but not CD8+ T cells. This represents an important difference to the ATPP 
approach that potently stimulates antigen-specific CD8+ CTLs, which have strikingly 
higher cytotoxic potential than CD4+ T cells. Since ATPPs release the delivered 
peptides within endosomes in a disulfide-dependent manner, they can be directly 
loaded into recycling MHC-I complexes without requiring further processing. This 
process is probably facilitated by endosomal acidification promoting the release of 
bound self-peptides192. As proven, ATPP-delivered peptides do not enter classical 
MHC-I antigen processing (Figure 7.17). In contrast, antigen-armed antibodies 
generated by Yu et al. depend on cellular antigen processing for the generation of 
mature peptides that can be loaded on MHC. However, endocytosed antigens are 
not accessible for the MHC-I antigen processing machinery that resides in the 
cytosol and ER, where it processes intracellular proteins192. Processing and 
presentation of exogenous antigen on MHC class I is restricted to cross-presenting 
DCs219. Therefore, these constructs disqualify for target cells only expressing MHC-I, 
hence excluding treatment of solid tumors. However, targeting of hematological 
malignancies allows processing along the MHC class II antigen presentation 
pathway and subsequent induction of CD4+ T cell responses. Nevertheless, ATPP-
mediated activation of CD8+ CTLs would probably induce stronger cytotoxic effects 
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compared to CD4+ T cell stimulation and ATPPs could presumably be employed to 
deliver MHC-II peptides, as well. 
The strategy that most closely resembles the ATPP approach has been published by 
Kang and colleagues220. They have generated a fully recombinant chimeric antibody 
containing immunogenic MHC-I peptides (OVA or E7 protein of human 
papillomavirus 16) incorporated into the Fc part and flanked by cleavage sites for the 
endoprotease furin. Similar to ATPPs, these molecules simply release immunogenic 
peptides independently of the cellular antigen processing machinery. Nevertheless, 
this approach requires expression of furin for the liberation of the delivered peptide 
epitopes. By targeting the ovarian cancer-associated antigen mesothelin, the 
compounds induced efficient (80-90%) lysis of mesothelin-transfected cancer cells 
by peptide-specific T cell lines in vitro at 0.5 to 0.05μg/mL. Although in vitro efficacy 
depends on a variety of assay-specific factors, such as E-T ratio or the type of 
utilized cancer and effector cells, the concentrations are comparable to those 
required for ATPP efficacy in vitro (0.132nM ≈ 0.02μg/mL). In vivo, Kang et al. 
observed very prominent anti-tumor effects when applying the mesothelin-targeting 
construct containing the OVA peptide, which mediated even slight regression of 
established ID8 tumors transfected with human mesothelin. Yet, tumor implantation, 
adoptive transfer of OT-I cells as well as drug administration was all performed 
intraperitonally, thus resulting in intratumoral injection of effector cells and test 
compounds, in turn compromising clinical transferability. As discussed above, it 
remains to be investigated how ATPPs will perform in a syngeneic setting. The major 
difference to the ATPP concept, however, represents the obscurity about the spatial 
occurrence of furin-mediated peptide release. Although the authors did not 
specifically address this question, their data suggest that cleavage may at least 
partially take place outside the cell. Most importantly, even mesothelin-negative cell 
lines were lysed by 20-30%, demonstrating that the peptides may not only be 
liberated extracellularly but also in the absence of target antigen. Given that furin 
additionally becomes highly upregulated at sites of inflammation221, these findings 
entail critical concerns in terms of off-target toxicity and suggest that furin-dependent 
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8.3. Comparison to clinically advanced T cell-based cancer immunotherapies 
While the aforementioned formulations have only experienced pre-clinical evaluation 
so far, advancement of the ATPP concept would eventually require comparison to 
clinical competitor technologies. Up to date, CAR-Ts and BiTEs represent the 
clinically most investigated and advanced therapeutic concepts. 
BiTEs have already proven substantial clinical value especially for the treatment of 
hematological malignancies and two compounds have been approved by the FDA 
for the treatment of malignant ascites and refractory B cell acute lymphoblastic 
leukemia168-173. A major advantage of BiTEs is their great potency. As these 
molecules trigger TCR activation by agonistically binding to the CD3 part, they 
stimulate T cells independently of their specificity, thereby mediating activation of a 
considerable pool of polyclonal T lymphocytes. At the same time, however, this 
feature is responsible for the two major side effects associated with BiTE therapy: 
Tumor lysis and cytokine release syndrome. While the former refers to the release of 
a tremendous amount of DAMPs due to the rapid lysis of a multitude of cancer cells, 
the latter results from simultaneous cytokine production by the plethora of activated 
T cells. In contrast to BiTEs, ATPP therapy only activates the antigen-specific sub-
population of the T cell repertoire, which possibly results in delayed tumoricidal 
effects. At the same time, however, the lower number of T cells activated in the first 
instance may simultaneously reduce cytokine release- and tumor lysis-associated 
side effects and thus allow better toxicity management in the beginning.  
The stimulation of a distinct, antigen-specific endogenous T cell repertoire by ATPPs 
entails additional advantages in terms of monitoring, controlling and even 
vaccination-based enhancement of the effector pool, as previously discussed. 
Moreover, the selective delivery of immunogenic, virus-derived peptides stimulates 
pre-existing memory T cells, which have life-long persistence and activity. These 
lymphocytes represent an already differentiated cell population that requires low 
doses of antigen, exhibits effector functions with fast kinetics and is less dependent 
on co-stimulation signals222-224, which are often absent in tumor microenvironments. 
Hence, the utilization of immunogenic MHC-I restricted peptides specifically 
stimulates a T cell repertoire with known effector memory phenotype, while 
circumventing the activation of potentially counterproductive T cell populations, such 
as Tregs or Th2 cells. This hypothesis is supported by recent findings from 
Schmittnaegel et al., who have compared cytokine release upon treatment with 
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BiTEs or peptide-MHC fusion molecules carrying the CMV-pp65 epitope. When 
using PBMCs as effectors, they could only detect Th2- and Treg-associated 
cytokines such as IL-4, IL-5 and IL-10 upon stimulation with BiTEs, but not when 
using their fusion molcules214. This scenario may especially be relevant in solid 
cancers that promote the generation and accumulation of immunosuppressive 
immune cells within the tumor microenvironment, putatively providing one reason for 
the compromised efficacy of BiTEs in solid versus hematological cancers. 
Besides BiTEs, CAR-Ts represent another technology that has generated significant 
clinical responses in patients with hematological malignancies. Recently the CD19-
targeting CART19 has been approved by the FDA for treatment of refractory B-
ALL176,177, highlighting the great therapeutic value of this approach. Similar to BiTEs, 
the major side effects of CAR-Ts are tumor lysis syndrome and cytokine storm due 
to the activation of large numbers of effector cells. As explained, CAR-Ts represent 
genetically engineered T cells expressing a chimeric antigen receptor, where target 
binding is mediated by an scFv-fragment. Thus, additional concerns about safety 
derive from insertional mutagenesis that might result from genetic manipulation and 
lead to T cell leukemia. Although the co-expression of so-called suicide genes has 
been proposed to selectively deplete the transferred CAR-T cell population175, 
genetic mutations or gene silencing (e.g. by methylation) might eventually trigger 
escape and outgrowth of certain clones. 
The generation of CAR-Ts requires collection of autologous T cells, sophisticated 
genetic engineering, in vitro expansion and infusion into the patient. This very time-
consuming procedure that has to be performed separately for each patient 
represents a substantial technological drawback of the concept, in turn limiting its 
large-scale applicability. In this respect, ATPPs exhibit superior utility, as they exploit 
an already pre-existing endogenous T cell repertoire and can be easily designed in a 
flexible, combinatorial manner allowing treatment of a broad patient population 
(further described below). Nevertheless, as ATPPs simply deliver immunogenic 
antigen, they depend on cellular MHC molecules, which may entail possible 
problems in cancers that frequently downregulate/lose HLA expression. These 
escape variants could potentially be targeted with therapies that do not rely on 
cellular HLA proteins, such as CAR-Ts, BiTEs or peptide-MHC fusions. 
All in all, every approach has specific assets and drawbacks and it remains to be 
elucidated which technology – also with regard to further sophistications – will 
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eventually exhibit the greatest therapeutic benefits for what type of malignancy. In 
general, reasoned combination of different immunotherapies may be beneficial and 
especially application of checkpoint inhibitors or co-stimulators (e.g. 4-1BB or OX40 
agonistic Abs or fusion molecules) with direct T cell-engaging approaches represents 
the most feasible and promising strategy at the moment. 
 
8.4. How to achieve tumor-specific delivery of immunogenic antigen 
The delivery of conjugated drugs or immunogenic antigens via antibodies aims at 
specifically targeting cancer cells while sparing healthy tissue, thereby limiting drug-
mediated toxicity and improving the therapeutic window. Therefore, the selection of a 
suitable target antigen is a crucial determinant of a drug´s efficacy and safety profile. 
As the primary aim of this thesis was to generate proof of concept data, the 
experiments have been mainly performed with the test antigen CDCP1. However, 
despite being upregulated in various cancer types, low to moderate CDCP1 
expression in several healthy tissues excludes its consideration as clinically relevant 
ATPP target188,189,225,226. Nevertheless, the presented data have revealed that the 
ATPP approach also works with other target antigens, as shown for CD22, CD79b 
and CD138 (Figure 7.10d, Figure 7.19). Moreover, cancer cell lines from different 
tissues could be efficiently lysed in vitro, in turn proving that intracellular peptide 
release and loading into MHC class I molecules is not limited to a specific cell type. 
These results prove the transferability of the therapeutic concept, hence raising the 
question for a suitable target antigen.  
In general, ATPP therapy requires a target that exhibits sufficient tumor specificity, 
cell surface expression and good internalization after antibody binding. Of note, the 
latter requirement fundamentally differs from target selection for BiTEs or peptide-
MHC fusions, as these rely on sustained, direct interaction with effector cells on the 
cell surface. Possibly, investigated CD22, CD79b or CD138 receptors may be 
promising ATPP targets. However, CAR-Ts and BiTEs have already proven 
significant clinical efficacy for the treatment of hematological malignancies.  
In solid tumors, target antigens require more thorough selection as simultaneous 
expression on healthy cells can lead to severe tissue-related toxicities. Cancer testis 
antigens are considered favorable targets with good safety profiles due to their high 
tumor-specificity. Yet, their utility for ATPP therapy is limited by the requirement of 
surface expression. Hence, an ideal, tumor-exclusive target might be difficult to find 
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or be not even available at the moment. However, even if target antigens are not 
tumor-restricted, additional specificity and safety may be achieved, when antibodies 
have limited access to the target on healthy versus malignant tissues. For instance, 
while being upregulated on several carcinomas, polarized expression of 
carcinoembryonic antigen (CEA, aka carcinoembryonic antigen-related cell adhesion 
molecule 5) only on the apical surface of glandular epithelial cells in the 
gastrointestinal system results in strikingly reduced accessibility by systemically 
administered antibodies227,228. These characteristics have already led to the 
development of a CEA-targeting BiTE that has proven pre-clinical efficacy and is 
being investigated in phase I clinical trials174.  
Nonetheless, the unique mode of action of ATPP conjugates might also allow 
targeting of other cancer-associated antigens, which exhibit low expression on 
healthy tissues (such as HER25,229, EGFR230,231 or mesothelin232-234). Especially the 
selection of growth receptors may result in enhanced tumor specificity due to cancer-
related aberrations in endocytic circuits. In normal cells, growth receptor 
engagement triggers internalization and subsequent sorting to lysosomal 
degradation as part of negative feedback mechanisms. In cancer cells, however, 
derailed endocytic pathways favor the recycling of these complexes to the cell 
surface to promote enhanced pro-tumorigenic signaling235,236. As ATPPs require and 
trigger receptor internalization, healthy cells will downregulate target expression 
upon treatment, whereas tumor cells will exhibit continuously high surface levels. 
This temporal aspect of target expression represents a crucial difference to other 
immunotherapies not relying on target internalization. With ATPPs, persisting antigen 
turnover will hence allow strikingly augmented delivery of immunogenic epitopes to 
cancer versus healthy cells and presumably result in a wider therapeutic window. 
Moreover, uncoupling of the targeting moiety and the T cell response-eliciting agent 
constitutes another important distinction to established technologies. Since 
antibodies can be loaded with differing amounts of peptide, there´s no predefined 
relation between target expression and T cell activation. As T cell activation depends 
on proper TCR clustering and hence requires a certain amount of peptide-MHC 
complexes on the cell surface, the possibility to selectively adapt the number of 
peptides delivered per antibody allows target-dependent modification, in order to 
achieve efficient lysis of cancer cells but sub-threshold delivery to healthy tissues. 
Nevertheless, every target antigen will eventually require detailed investigation, as 
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the safety and efficacy profile surely significantly depends on the inherent properties 
of the target (expression levels, internalization efficacy, turnover), as well as on the 
characteristics of the utilized antibody (affinity, pharmacokinetics) and the conjugated 
peptide (affinity to MHC, T cell affinity to peptide-MHC complexes). 
 
8.5. Further sophistication of conjugate design 
Aside from the target antigen, the conjugate design decisively influences a drug´s 
efficacy and safety profile. For instance, the pharmacokinetic plays a critical role in 
defining these features. In this respect, IgG antibodies – that constitute the backbone 
of the utilized ATPP conjugates – have a half-life of up to 4 weeks, depending on the 
influence of target-mediated clearance. Yet, in theory, ATPPs could also be 
generated with scFv or Fab molecules, e.g. to achieve better tissue/tumor 
penetration owing to the reduced molecular size. The size of ATPP conjugates is 
mainly defined by the antibody part, as linkers and peptides are very small, hence 
not exceeding 150-160kDa. Given that microvascular permeability only varied 2-fold 
in the range of 25-160kDa as determined in a xenografted human colon 
adenocarcinoma model237,  the usage of antibody fragments lacking the Fc-part may 
be counterproductive, as these molecules will have strikingly reduced half-lives (24-
48h) due to missing FcRn binding and faster renal clearance238-240. Therefore, the 
usage of full-length antibody molecules seems favorable. The possible drawback of 
FcγR-mediated clearance has already been addressed in utilized ATPP conjugates 
by introducing the P329G LALA mutation into the Fc-part195. Moreover, the utilization 
of humanized antibodies in combination with the simple design of ATPP conjugates 
will help to reduce the risk for anti-drug antibodies that mediate enhanced clearance 
in kidney and liver239. 
On the molecular basis, targeted peptide conjugation should be applied, in order to 
reduce intermolecular heterogeneity between ATPP conjugates. ATPPs utilized in 
this study, were generated by randomly conjugating SPDP-linked peptides to lysine 
residues on the antibodies, hence precluding a defined antibody-peptide-ratio, which 
represents an important regulatory element to fine-tune therapeutic efficacy and 
safety. In this respect, site-specific conjugation has already been reported to not only 
preclude drug heterogeneity, but to simultaneously improve conjugate stability, 
pharmacokinetics as well as to potentially enlarge the therapeutic window241. 
Moreover, random conjugation could theoretically affect antibody affinity or even 
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specificity e.g. when binding within complementarity determining regions (CDRs). 
Although we could not detect differences in target binding or internalization, the 
applied conjugation process represents a potential drawback.  
With respect to the utilized SPDP linker, it remains to be confirmed that these 
conjugates are stable in circulating blood of patients. Though, in theory, other linker 
formats could be tested241. Nevertheless, it will be of major importance that the 
peptides are released in the correct intracellular compartment that allows transfer on 
recycling MHC molecules. 
Further on, clinical applicability of the ATPP technology requires generation of 
immunoconjugates that allow treatment of a broad patient population. Therefore, the 
delivered peptide epitopes should be selected relating to the frequency of respective 
HLA genes and the abundance of peptide-specific T cells. In addition, differing 
binding affinities of peptides to the respective MHC molecules or varying TCR 
affinities for the cognate peptide-MHC complex may play important roles in 
determining the therapeutic potential.  
In the performed experiments we have chosen immunodominant epitopes that bind 
to the high frequency HLA allotypes HLA-A2:01 and HLA-A1:01242,243 and derive 
from viruses with high seroprevalence (EBV244-246, Influenza A247,248). Moreover, it is 
well known that CD8+ cytotoxic T cells against these viruses are maintained at high 
frequencies in the circulation of healthy persons and cancer patients and can be 
functionally reactivated upon antigen rechallenge249-251. Nevertheless, a 
combinatorial approach by conjugating multiple, varying peptide epitopes per 
antibody seems reasonable, in order to increase the pool of activated T cells and to 
allow treatment of a larger patient population. Along this line, the utilization of 
additional antigenic epitopes, against which memory T cells exists in the majority of 
the human population (e.g. CMV252,253 or from vaccines against polio or hepatitis 
viruses), may be favorable. As mentioned above, specific vaccinations could 
additionally be applied prior to ATPP treatment, in order to induce or boost the 
respective effector memory pool. Besides increasing the therapeutic coverage of the 
patient population, employing various peptides with different HLA-restrictions may 
additionally counteract the emergence of tumor escape variants that e.g. 
downregulate or lose expression of certain HLA molecules.  
In terms of feasibility, usage of the biotin-streptavidin system, conjugating Abs and 
peptide linkers in a two-step process, may even help to achieve personalized 
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therapeutics. Although streptavidin has been shown to elicit significant immune 
responses in humans, in turn limiting its utility, recent approaches of targeted 
mutagenesis have generated promising data in reducing its immunogenicity while 
preserving the core functions of biotin binding254,255.  
Taking together, our data demonstrate that ATPPs can trigger T cell activation 
against cancer cells from multiple cancer types by targeting different surface 
antigens and delivering immunogenic peptide epitopes with varying HLA restrictions. 
These immunoconjugates efficiently mediated lysis of targeted cancer cells in vitro 
and in vivo, hence providing evidence for a broad therapeutic applicability. 
Fundamental differences in the biological functionality of the ATPP technology 
compared to existing immunotherapies may open new avenues for therapeutic 
applications, possibly also in cancers that resist or escape current treatment 
strategies. As proven by the presented data, combined treatment with existing 
immunotherapies, especially with checkpoint inhibitors, suggests great potential for 
cancer therapy. Further pre-clinical and clinical research is required, especially with 
respect to the target antigen, in order to further advance this innovative and 
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Supplemental Figure 9.1 Mass spectrometric analysis of peptide labeling rates of ATPP 
immunoconjugates. 
Mean peptide labeling rates of ATPP conjugates were determined by HPLC-MS after deglycosylation 
using N-glycosidase F. (a) ESI-MS spectrum of unlabeled αCDCP1 Ab. (b) ESI-MS spectrum of 
αCDCP1-CLG ATPP with SPDP linker and EBV_CLG peptide. (c) Calculation of mean peptide 
labeling rate of the αCDCP1-CLG ATPP as derived from (b). (d) Mean peptide labeling rates of all 
utilized ATPP conjugates. Data were generated by Dominic Knoblauch in the laboratory of Gloria 
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